Ceftazidime

Class: Third Generation Cephalosporins
Chemical Name: [6R-[6α,7β(Z)]]-1-[[7-[[(2-Amino-4-thiazolyl) [(1 - carboxy - 1 - methylethoxy)imino]acetyl]amino] - 2 - carboxy - 8 - oxo - 5 - thia - 1 - azabicyclo[4.2.0]oct - 2 - en - 3 - yl]methyl] pyridinium hydroxide, inner salt, pentahydrate
CAS Number: 78436-06-2
Brands: Fortaz, Tazicef

Introduction

Antibacterial; β-lactam antibiotic; third generation cephalosporin.¹ ³ ⁷ ¹⁰ ⁴⁵ ⁵⁰ ⁵³ ⁵⁴ ⁵⁶ ¹⁴⁷ ¹⁵⁰ ²⁰³ ²¹⁷

Uses for Ceftazidime

Bone and Joint Infections

Treatment of bone and joint infections caused by susceptible Staphylococcus aureus (methicillin-susceptible [oxacillin-susceptible] strains only) Klebsiella, or Pseudomonas aeruginosa.¹ ¹⁰⁴ ¹¹⁸ ¹³⁶ ²¹⁷ ²⁵¹ ²⁹⁸

Intra-abdominal and Gynecologic Infections

Treatment of gynecologic infections (including endometritis, pelvic cellulitis, other infections of the female genital tract) caused by susceptible Escherichia coli.¹ ²¹⁷ ²⁵¹

Treatment of intra-abdominal infections (including peritonitis) caused by susceptible S. aureus (oxacillin-susceptible strains only), E. coli, or Klebsiella.¹ ²¹⁷ ²⁵¹

Treatment of polymicrobial intra-abdominal infections caused by susceptible aerobic and anaerobic bacteria and Bacteroides.¹ ¹³⁶ ¹³⁷ ²¹⁷ ²⁵¹ Consider that many strains of B. fragilis are resistant; generally should not be used alone in serious intra-abdominal infections when this organism may be involved.¹ ²¹⁷ ²⁵¹ ^a

For initial empiric treatment of high-risk or severe community-acquired extrabiliary intra-abdominal infections in adults, IDSA recommends either monotherapy with a carbapenem (doripenem, imipenem, meropenem) or the fixed combination of piperacillin and tazobactam, or a combination regimen that includes either a cephalosporin (cefepime, ceftazidime) or fluoroquinolone (ciprofloxacin, levofloxacin) in conjunction with metronidazole.⁷⁰

Meningitis and Other CNS Infections

Treatment of meningitis caused by susceptible H. influenzae, Neisseria meningitidis, Ps. aeruginosa, or Streptococcus pneumoniae in adults or children.¹ ⁴⁶ ⁴⁷ ⁵⁰ ¹³⁷ ²¹⁷ ²⁵¹ ²⁵⁴

Ceftazidime in conjunction with an aminoglycoside considered a regimen of choice for treatment of meningitis caused by susceptible P. aeruginosa¹³ ¹⁴ ¹¹² ¹⁴⁷ ¹⁹⁷ ³³⁷ ³⁵⁴ or susceptible Enterobacteriaceae† (e.g., E. coli, P. mirabilis, Enterobacter, S. marcescens).⁴⁶ ⁴⁷ ²²² ²²³ ²²⁴ ³³⁵

Cefotaxime or ceftriaxone generally preferred when a third generation cephalosporin is indicated for treatment of meningitis caused by H. influenzae, N. meningitidis, or S. pneumoniae.⁴⁷ ¹⁵⁰ ¹⁹⁷ ²¹⁶ ³³⁵ ³³⁶ ³³⁷ ³³⁸

Respiratory Tract Infections

Treatment of respiratory tract infections (including pneumonia) caused by susceptible S. aureus (methicillin-susceptible [oxacillin-susceptible] strains only), S. pneumoniae, Citrobacter, Enterobacter, E. coli, Klebsiella, Proteus mirabilis, Pseudomonas (including Ps. aeruginosa), or Serratia.¹ ¹⁰³ ¹⁰⁸ ¹¹⁷ ¹¹⁸ ¹¹⁹ ¹²⁰ ¹³⁷ ¹⁴³ ¹⁴⁴ ¹⁴⁶ ¹⁴⁷ ¹⁴⁸ ²¹⁷ ²⁵¹

For treatment of community-acquired pneumonia (CAP) caused by Ps. aeruginosa, ATS and IDSA recommend a combination regimen that includes an antipseudomonal β-lactam (cefepime, ceftazidime, aztreonam, imipenem, meropenem, piperacillin, ticarcillin) given in conjunction with ciprofloxacin, levofloxacin, or an aminoglycoside.²²⁷

Septicemia

Treatment of septicemia caused by susceptible S. aureus (methicillin-susceptible [oxacillin-susceptible] strains only), S. pneumoniae, Haemophilus influenzae, E. coli, Klebsiella, Ps. aeruginosa, or Serratia.¹ ¹¹⁵ ¹¹⁸ ¹¹⁹ ¹²⁰ ¹⁴⁶ ²¹⁷ ²⁵¹

Select anti-infective for treatment of sepsis syndrome based on probable source of infection, causative organism, immune status of patient, and local patterns of bacterial resistance.¹⁹⁷

For initial treatment of life-threatening sepsis in adults, some clinicians suggest that a third or fourth generation cephalosporin (cefepime, cefotaxime, ceftriaxone, ceftazidime), the fixed combination of piperacillin and tazobactam, or a carbapenem (doripenem, imipenem, meropenem) be used in conjunction with vancomycin; some also suggest including an aminoglycoside or fluoroquinolone during initial few days of treatment.¹⁹⁷

Skin and Skin Structure Infections

Treatment of skin and skin structure infections caused by susceptible S. aureus (oxacillin-susceptible strains only), S. pyogenes (group A β-hemolytic streptococci), Enterobacter, E. coli, Klebsiella, Proteus (including P. mirabilis), Ps. aeruginosa, or Serratia.¹ ¹¹⁵ ¹¹⁸ ¹¹⁹ ¹²⁰ ¹³⁶ ¹⁴⁶ ²¹⁷ ²⁵¹

Urinary Tract Infections (UTIs)

Treatment of uncomplicated and complicated UTIs caused by susceptible Enterobacter, E. coli, Klebsiella, Proteus (including P. mirabilis), Ps. aeruginosa, or Serratia.¹ ¹⁰⁶ ¹¹³ ¹¹⁵ ¹¹⁸ ¹¹⁹ ¹³⁷ ¹⁴¹ ¹⁴⁵ ¹⁵³ ²¹⁷

Burkholderia Infections

Treatment of septicemia or pulmonary infections caused by Burkholderia cepacia† (formerly Ps. cepacia);¹⁴⁷ ¹⁹⁷ ²⁰⁸ ³⁴⁵ alone or in conjunction with an aminoglycoside.¹⁴⁷ ¹⁹⁷ ²⁰⁸ ³⁴⁵ Co-trimoxazole considered drug of choice; ceftazidime, chloramphenicol, or imipenem are alternatives.¹⁹⁷

Treatment of melioidosis† caused by B. pseudomallei (formerly Ps. pseudomallei).¹⁹⁷ ²⁶⁴ ²⁶⁶ ²⁶⁷ ²⁷⁶ ²⁷⁷ ³⁴⁶ ³⁵⁵ ³⁵⁶ ³⁵⁷ ³⁵⁸ Usually treated with initial parenteral regimen of ceftazidime, imipenem, or meropenem (some clinicians recommend co-trimoxazole also be included, especially if patient is septicemic) followed by prolonged maintenance with oral anti-infectives (e.g., co-trimoxazole with or without doxycycline).²⁷⁵ ³⁵⁵ ³⁵⁶ ³⁵⁷ ³⁵⁸ B. pseudomallei is difficult to eradicate (relapse of melioidosis is common).²⁶⁴ ²⁶⁶ ²⁷⁶ ³⁴⁶ ³⁵⁵

Otitis Externa

Treatment of malignant otitis externa† caused by Ps. aeruginosa.³⁵² ³⁵³

Acute bacterial otitis externa localized in the external auditory canal may be effectively treated using topical anti-infectives (e.g., otic preparations of ciprofloxacin or ofloxacin), but malignant otitis externa is an invasive, potentially life-threatening infection (especially in immunocompromised patients such as those with diabetes mellitus or HIV infection) and requires prompt diagnosis and long-term treatment with parenteral anti-infectives (e.g., ceftazidime and/or ciprofloxacin).³⁵² ³⁵³

Pseudomonas aeruginosa Infections

Generally considered a drug of choice for treatment of infections caused by Ps. aeruginosa,⁵⁰ ⁵⁷ ¹⁴⁷ ¹⁸⁶ ¹⁹⁸ including acute exacerbations of bronchopulmonary Ps. aeruginosa infections in children and adults with cystic fibrosis.²⁸ ¹¹⁹ ¹²⁵ ¹²⁶ ¹²⁸ ¹²⁹ ¹³⁰ ¹³² ¹³⁴ ¹⁴⁷ ¹⁵⁰ ¹⁵⁴ ²⁰⁸ ²⁴⁶ ³¹³ ³³² ³⁴⁸

In severe infections, especially in immunocompromised patients, concomitant use of ceftazidime and an aminoglycoside (e.g., amikacin, gentamicin, tobramycin) is recommended.¹⁹⁷ Consider that ceftazidime-resistant strains of Ps. aeruginosa can emerge during therapy and superinfection with resistant strains has occurred.⁵⁰ ¹¹¹ ¹¹⁵ ¹⁴⁷

Anti-infective therapy in patients with cystic fibrosis may result in clinical improvement and Ps. aeruginosa may be temporarily cleared from the sputum, but a bacteriologic cure is rarely obtained and should not be expected.²⁸ ¹¹⁹ ¹²⁵ ¹²⁶ ¹³² ¹⁴⁹ ¹⁵⁰ ²⁰⁸ ²⁴⁶ ³¹³

Vibrio Infections

Treatment of infections caused by Vibrio vulnificus†.²¹⁹ ²⁵⁶

Optimum anti-infective therapy has not been identified; a tetracycline or third generation cephalosporin (e.g., cefotaxime, ceftazidime) is recommended.¹⁹⁷ ²¹⁹ ²⁵⁶ Because the case fatality rate associated with V. vulnificus is high, initiate anti-infective therapy promptly if indicated.²⁵⁶ ²⁶²

Empiric Therapy in Febrile Neutropenic Patients

Has been used alone or in conjunction with an aminoglycoside for empiric treatment of presumed bacterial infections in febrile neutropenic adults or children†.¹²² ¹²³ ¹²⁴ ¹³⁸ ¹³⁹ ¹⁴⁰ ²¹² ²²⁸ ²⁴⁷ ²⁴⁸ ²⁴⁹ ²⁶¹ ²⁷⁹ ²⁸⁰ ²⁸⁶ ²⁸⁷ ²⁸⁸ ²⁸⁹ ²⁹⁰ ²⁹¹ ²⁹² ²⁹⁴ ²⁹⁵ ³⁴⁷ ³⁴⁹

IDSA states that ceftazidime is no longer a reliable agent for empiric monotherapy in febrile neutropenic patients because of decreasing potency against gram-negative bacteria and poor activity against many gram-positive bacteria (e.g., streptococci).³⁹⁰

Consult published protocols for the treatment of infections in febrile neutropenic patients for specific recommendations regarding selection of the initial empiric regimen, when to change the initial regimen, possible subsequent regimens, and duration of therapy in these patients.³⁹⁰ Consultation with an infectious disease expert knowledgeable about infections in immunocompromised patients also is advised.³⁹⁰

Perioperative Prophylaxis

Has been used for perioperative prophylaxis† in patients undergoing vaginal hysterectomy,¹⁵¹ biliary or intra-abdominal surgery,¹⁶⁷ ¹⁶⁹ or transurethral resection of the prostate.¹⁴²

First or second generation cephalosporins (cefazolin, cefotetan, cefoxitin, cefuroxime) generally preferred when a cephalosporin used for perioperative prophylaxis.¹⁶⁸ ¹⁶⁹ Third generation cephalosporins (cefotaxime, ceftriaxone, ceftazidime) and fourth generation cephalosporins (cefepime) not usually recommended for perioperative prophylaxis since they are expensive, some are less active against staphylococci than first or second generation cephalosporins, they have spectrums of activity wider than necessary for organisms encountered in elective surgery, and their use for prophylaxis may promote emergence of resistant organisms.¹⁶⁸ ¹⁶⁹

Ceftazidime Dosage and Administration

Administration

Administer by intermittent IV injection or infusion or by deep IM injection.¹ ²¹⁷ Also has been administered by continuous IV infusion†.²⁹⁹ ³⁰⁰ ³⁰¹ ³⁰² ³¹⁰ ³³² ³⁴⁸

Has been administered intraperitoneally in dialysis solutions.¹ ²⁷ ²¹⁷ Should not be administered by intra-arterial injection since necrosis can occur.¹ ²¹⁷

IV route preferred for treatment of septicemia, meningitis, peritonitis, or other severe or life-threatening infections and in patients with lowered resistance resulting from malnutrition, trauma, surgery, diabetes, heart failure, or malignancy, particularly if shock is present or impending.¹ ²¹⁷

The commercially available frozen ceftazidime injection in dextrose should be used only for IV infusion.¹

For solution and drug compatibility information, see Compatibility under Stability.

IV Injection

Reconstitution

For intermittent IV injection, reconstitute vials containing 500 mg, 1 g, or 2 g with 5.3 mL, 10, or 10 mL, respectively, of sterile water for injection to provide solutions containing approximately 100, 100, or 170 mg/mL, respectively.¹ ²¹⁷

Shake vial after adding the diluent;¹ ²¹⁷ carbon dioxide is released as drug dissolves and the solution will become clear within 1–2 minutes.¹ ²¹⁷ When withdrawing a dose from reconstituted vials, consider that the solution may contain some carbon dioxide bubbles which should be expelled from the syringe before injection.¹ ²¹⁷

Rate of Administration

Inject appropriate dose of reconstituted solution into a vein over a period of 3–5 minutes or slowly into the tubing of a compatible IV solution.¹ ²¹⁷

IV Infusion

Reconstitution and Dilution

Reconstitute vials of containing 1 or 2 g of ceftazidime with 100 mL of sterile water for injection or compatible IV solution.¹ ²¹⁷ Shake the vial after adding the diluent;¹ ²¹⁷ carbon dioxide is released as the drug dissolves and the solution will become clear within 1–2 minutes.¹ ²¹⁷ The appropriate dose of the drug should then be added to a compatible IV solution.¹ ²¹⁷

Reconstitute pharmacy bulk packages according to the manufacturer’s directions and then further dilute in a compatible IV infusion solution prior to administration.¹ ²³³

ADD-Vantage or TwistVialvials labeled as containing 1 or 2 g of ceftazidime should be reconstituted according to the manufacturer’s directions.¹ ²¹⁷

Reconstitute (activate) commercially available Duplex drug delivery system containing 1 or 2 g of ceftazidime and 50 mL of 5% dextrose injection in separate chambers according to the manufacturer's directions.²⁵¹ If refrigerated after reconstitution (see Storage under Stability), allow solution to reach room temperature prior to administration.²⁵¹

Thaw commercially available premixed injection (frozen) at room temperature (25°C) or under refrigeration (5°C); do not thaw by immersion in a water bath or by exposure to microwave radiation.¹ A precipitate may have formed in the frozen injection, but should dissolve with little or no agitation after reaching room temperature.¹ Discard thawed injection if an insoluble precipitate is present or if container seals or outlet ports are not intact or leaks are found.¹ Do not use in series connections with other plastic containers; such use could result in air embolism from residual air being drawn from the primary container before administration of fluid from secondary container is complete.¹

Rate of Administration

Intermittent IV infusions generally have been infused over 15–30 minutes in adults,⁸ ¹⁰² ¹⁰⁴ ¹⁰⁵ ¹¹⁵ ¹¹⁶ ¹¹⁸ ¹¹⁹ ¹³³ ¹³⁷ ¹³⁹ ¹⁴⁴ neonates,³⁴ and children.¹⁰⁸ ¹⁵⁷

If a Y-type administration set is used, the other solution flowing through the tubing should be discontinued while ceftazidime is being infused.¹ ²¹⁷ ²⁶²

IM Injection

IM injections should be made deeply into a large muscle mass, such as the upper outer quadrant of the gluteus maximus or lateral part of the thigh.¹ ²¹⁷

Reconstitution

IM injections are prepared by adding 1.5 or 3 mL of sterile or bacteriostatic water for injection or 0.5 or 1% lidocaine hydrochloride injection to vials containing 500 mg or 1 g of ceftazidime, respectively, to provide solutions containing approximately 280 mg/mL.¹

Shake the vial after adding the diluent;¹ ²¹⁷ carbon dioxide is released as the drug dissolves and the solution will become clear within 1–2 minutes.¹ ²¹⁷ When withdrawing a dose from reconstituted vials, consider that the solution may contain some carbon dioxide bubbles which should be expelled from the syringe before injection.¹ ²¹⁷

Intraperitoneal Instillation

Reconstitute with sterile water for injection as for IV infusion²²¹ and then further dilute in a compatible peritoneal dialysis solution to provide a solution containing 250 mg of ceftazidime in each 2 L of dialysis solution.¹ ²¹⁷

Dosage

Available as ceftazidime pentahydrate and as ceftazidime sodium; dosage expressed as anhydrous ceftazidime.¹ ³ ²¹⁷

Do not use ceftazidime available in Duplex containers in patients who require less than entire 1- or 2-g dose in the container.²⁵¹

Pediatric Patients

General Dosage for Neonates

IV

Neonates ≤4 weeks of age: Manufacturer recommends 30 mg/kg every 12 hours.¹ ²¹⁷

Neonates ≤7 days of age: AAP recommends 50 mg/kg every 12 hours, regardless of weight.²⁷⁵

Neonates 8–28 days of age: AAP recommends 50 mg/kg every 8–12 hours in those weighing ≤2 kg and 50 mg/kg every 8 hours in those weighing >2 kg.²⁷⁵

General Dosage for Infants and Children 1 Month to 12 Years of Age

IV

25–50 mg/kg every 8 hours.¹ ³⁸ ¹⁰³ ¹⁰⁷ ²¹⁷ ²⁵⁴ Use 50 mg/kg every 8 hours in immunocompromised children or children with cystic fibrosis.¹ ²⁸ ³⁰ ¹⁰⁸ ¹²⁶ ¹²⁸ ¹²⁹ ¹⁴⁹ ²¹⁷

Children beyond neonatal period: AAP recommends 90–150 mg/kg daily in 3 equally divided doses for the treatment of mild to moderate infections or 200–300 mg/kg daily in 3 equally divided doses for treatment of severe infections.²⁷⁵

General Dosage for Children >12 Years of Age

IV

Use usual adult dosage.¹ ²¹⁷ (See Adult Dosage under Dosage and Administration.)

Meningitis

IV

Some clinicians recommend 100–150 mg/kg daily in 2 or 3 equally divided doses for neonates ≤7 days of age and 150 mg/kg daily in 3 divided doses in older neonates and children.³⁵⁴

Because of a high rate of relapse, treatment duration should be ≥3 weeks for meningitis caused by gram-negative bacilli.³³⁵ ³³⁷ ³⁵⁴ In neonates, some clinicians recommend that treatment be continued for 2 weeks beyond the first sterile CSF culture or at least 3 weeks, whichever is longer.³⁵⁴

Burkholderia Infections†

Severe Melioidosis Caused by Burkholderia pseudomallei†

Children ≥2 months of age: 60 mg/kg daily in 2 equally divided doses recommended by some clinicians for children <2 months of age or 100 mg/kg daily in 3 equally divided doses.³⁵⁷ Concomitant co-trimoxazole or doxycycline may be indicated in septicemic or other severe cases.³⁵⁷

Continue initial parenteral regimen for at least 10–14 days and until there is clinical improvement.²⁷⁵ ³⁵⁵ ³⁵⁶ ³⁵⁷ When appropriate, switch to oral maintenance regimen (e.g., oral co-trimoxazole with or without oral doxycycline) and continue for at least 3–6 months to prevent recrudence or relapse.²⁷⁵ ³⁵⁵ ³⁵⁶ ³⁵⁷ More prolonged oral maintenance therapy (up to 12 months) may be necessary, depending on the response to therapy and severity of initial illness.³⁵⁶ ³⁵⁷

Empiric Therapy in Febrile Neutropenic Children†

50 mg/kg (maximum 2 g) every 8 hours has been used in pediatric patients ≥2 years of age.³⁴⁷

Adults

General Adult Dosage

Less Severe Infections

IV or IM

1 g every 8–12 hours.¹ ²¹⁷

Severe or Life-threatening Infections

2 g every 8 hours,¹ especially in immunocompromised patients.¹

Bone and Joint Infections

IV

2 g every 12 hours.¹ ¹⁰⁴ ²¹⁷

Intra-abdominal and Gynecologic Infections

Serious Infections

2 g every 8 hours.¹ ²¹⁷

Meningitis

IV

2 g every 8 hours.¹ ²¹⁷ ³⁵⁴ Duration of treatment is ≥3 weeks for meningitis caused by susceptible gram-negative bacilli.³³⁵ ³³⁷ ³⁵⁴

Respiratory Tract Infections

Uncomplicated Pneumonia

IV or IM

0.5–1 g every 8 hours.¹ ²¹⁷

Pseudomonas Lung Infections in Cystic Fibrosis Patients

30–50 mg/kg every 8 hours (up to 6 g daily).¹ ²⁸ ³⁰ ⁵⁰ ¹²⁵ ¹²⁶ ¹²⁸ ¹²⁹ ¹⁴⁹ ²¹⁷ ²⁴⁶ ³⁴⁸

Clinical improvement may occur, but bacteriologic cures should not be expected in patients with chronic respiratory disease and cystic fibrosis.¹ ²⁸ ¹¹⁹ ¹²⁵ ¹²⁶ ¹³² ¹⁴⁹ ¹⁵⁰ ²⁰⁸ ²¹⁷

Skin and Skin Structure Infections

Mild Infections

IV or IM

0.5–1 g every 8 hours.¹ ¹⁰⁴ ²¹⁷

Urinary Tract Infections (UTIs)

Uncomplicated Infections

IV or IM

250 mg every 12 hours.¹ ¹⁰⁴ ²¹⁷

Complicated Infections

IV or IM

500 mg every 8–12 hours.¹ ¹⁰⁴ ²¹⁷

Burkholderia Infections†

Severe Melioidosis Caused by Burkholderia pseudomallei†

40 mg/kg every 8 hours recommended by US Army Medical Research Institute of Infectious Diseases (USAMRIID).³⁵⁶ Others recommend 2 g every 8 hours (up to 6 g daily)³⁵⁷ or 50 mg/kg (up to 2 g) every 6 hours.³⁵⁵ ³⁵⁸ Concomitant co-trimoxazole or doxycycline may be indicated in septicemic or other severe cases.³⁵⁵ ³⁵⁶ ³⁵⁷ ³⁵⁸

Continue initial parenteral regimen for at least 10–14 days and until there is clinical improvement.²⁷⁵ ³⁵⁵ ³⁵⁶ ³⁵⁷ ³⁵⁸ When appropriate, switch to an oral maintenance regimen (e.g., oral co-trimoxazole with or without oral doxycycline) and continue for at least 3–6 months to prevent recrudence or relapse.²⁷⁵ ³⁵⁵ ³⁵⁶ ³⁵⁷ ³⁵⁸ More prolonged oral maintenance therapy (up to 12 months) may be necessary, depending on the response to therapy and severity of initial illness.³⁵⁶ ³⁵⁷

Empiric Therapy in Febrile Neutropenic Patients†

IV

100 mg/kg daily in 3 divided doses or 2 g every 8 hours either alone or in conjunction with an aminoglycoside (amikacin, gentamicin, tobramycin) has been used.²⁶¹ ²⁷⁹ ²⁸⁰ ²⁸⁶ ²⁹⁰ ²⁹² ²⁹⁵ ³⁴⁹

Prescribing Limits

Pediatric Patients

Maximum 6 g daily.¹

Adults

Maximum 6 g daily.¹ ²¹⁷ ²²¹ ²²⁵

Special Populations

Hepatic Impairment

Dosage adjustments not required unless renal function also impaired.¹ ¹⁵⁰ ²¹⁷

Renal Impairment

Reduce dosage in patients with Cl_cr ≤50 mL/minute.¹ ²¹⁷

Manufacturers recommend that adults with Cl_cr ≤50 mL/minute receive an initial loading dose of 1 g and a maintenance dosage based on Cl_cr.¹ ²¹⁷ (See Table.)

Maintenance Dosage for Adults with Renal Impairment1
Cl_cr (mL/minute)	Dosage
31–50	1 g every 12 h
16–30	1 g every 24 h
6–15	500 mg every 24 h
<5	500 mg every 48 h

Patients with renal impairment and severe infections who would generally receive 6 g daily if renal function were normal: increase dosage in table by 50% or dosing interval may be increased appropriately.¹

Patients undergoing hemodialysis: given an initial loading dose of 1 g followed by 1 g after each hemodialysis period.¹ ²¹⁷ ²²¹

Patients undergoing intraperitoneal dialysis or CAPD: given an initial loading dose of 1 g followed by 500 mg every 24 hours.¹ ²¹⁷ ²²¹

Geriatric Patients

Cautious dosage selection because of age-related decreases in renal function.¹ (See Renal Impairment under Dosage and Administration.)

Cautions for Ceftazidime

Contraindications

Known hypersensitivity to ceftazidime or other cephalosporins.¹

Warnings/Precautions

Warnings

Superinfection/Clostridium difficile-associated Diarrhea and Colitis (CDAD)

Possible emergence and overgrowth of nonsusceptible organisms with prolonged therapy.¹ Careful observation of the patient is essential.¹ ²¹⁷ Institute appropriate therapy if superinfection occurs.¹ ²¹⁷

Treatment with anti-infectives alters normal colon flora and may permit overgrowth of Clostridium difficile.¹ C. difficile infection (CDI) and C. difficile-associated diarrhea and colitis (CDAD; also known as antibiotic-associated diarrhea and colitis or pseudomembranous colitis) reported with nearly all anti-infectives, including ceftazidime, and may range in severity from mild diarrhea to fatal colitis.¹ ²¹⁷ ³⁴⁰ ³⁴¹ ³⁴² C. difficile produces toxins A and B which contribute to development of CDAD;¹ ²¹⁷ ³⁴⁰ hypertoxin-producing strains of C. difficile are associated with increased morbidity and mortality since they may be refractory to anti-infectives and colectomy may be required.¹ ²¹⁷

Consider CDAD if diarrhea develops and manage accordingly.¹ ²¹⁷ ³⁴⁰ ³⁴¹ ³⁴² Obtain careful medical history since CDAD may occur as late as 2 months or longer after anti-infective therapy is discontinued.¹ ²¹⁷ ³⁴⁰

If CDAD is suspected or confirmed, discontinue anti-infectives not directed against C. difficile whenever possible.¹ ²¹⁷ ³⁴⁰ Initiate appropriate supportive therapy (e.g., fluid and electrolyte management, protein supplementation), anti-infective therapy directed against C. difficile (e.g., metronidazole, vancomycin), and surgical evaluation as clinically indicated.¹ ²¹⁷ ³⁴⁰ ³⁴¹ ³⁴²

Neurotoxicity

Possibility of seizures, encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia if inappropriately high dosage used in patients with renal impairment.¹ (See Renal Impairment under Cautions.)

Sensitivity Reactions

Hypersensitivity Reactions

Possible hypersensitivity reactions, including rash (maculopapular or erythematous), pruritus, fever, eosinophilia, urticaria, anaphylaxis, erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis.¹ ²¹⁷ ^a

Hypersensitivity reactions, including anaphylaxis, reported with dextrose-containing solutions;²⁵¹ usually reported in patients receiving high dextrose concentrations (i.e., 50% dextrose), but also reported when corn-derived dextrose solutions administered to patients with or without history of hypersensitivity to corn products.²⁵¹

If an allergic reaction occurs, discontinue and institute appropriate therapy as indicated (e.g., epinephrine, corticosteroids, maintenance of an adequate airway, oxygen).¹ ²¹⁷

Cross-hypersensitivity

Partial cross-sensitivity among cephalosporins and other β-lactam antibiotics, including penicillins and cephamycins.¹ ²¹⁷ ^a

Prior to initiation of therapy, make careful inquiry concerning previous hypersensitivity reactions to cephalosporins, penicillins, or other drugs.¹ ²¹⁷ Cautious use recommended in individuals hypersensitive to penicillins:¹ ²¹⁷ ^a avoid use in those who have had an immediate-type (anaphylactic) hypersensitivity reaction and administer with caution in those who have had a delayed-type (e.g., rash, fever, eosinophilia) reaction.^a

General Precautions

History of GI Disease

Use with caution in patients with a history of GI disease, particularly colitis.¹ ²¹⁷ (See Superinfection/Clostridium difficile-associated Diarrhea and Colitis under Cautions.)

Prolonged PT

Possibility of prolonged PT.¹ ²¹⁷

Monitor PT in patients at risk, including those with renal or hepatic impairment, poor nutritional state, receiving prolonged therapy, or stabilized on anticoagulant therapy.¹ ²¹⁷ Administer vitamin K when indicated.¹ ²¹⁷

Selection and Use of Anti-infectives

To reduce development of drug-resistant bacteria and maintain effectiveness of ceftazidime and other antibacterials, use only for treatment or prevention of infections proven or strongly suspected to be caused by susceptible bacteria.¹ ²¹⁷

When selecting or modifying anti-infective therapy, use results of culture and in vitro susceptibility testing.¹ ²¹⁷ In the absence of such data, consider local epidemiology and susceptibility patterns when selecting anti-infectives for empiric therapy.¹ ²¹⁷

Resistance in Gram-negative Bacteria

Resistance caused by inducible type I β-lactamases can develop in some gram-negative bacilli (e.g., Enterobacter, Pseudomonas, Serratia) during treatment, leading to clinical failure in some cases.¹

When treating infections caused by these bacteria, perform periodic in vitro susceptibility testing when clinically appropriate.¹ If patient fails to respond to monotherapy, an aminoglycoside or similar agent should be considered.¹

Risk of Distal Necrosis

Possibility of distal necrosis after inadvertent intra-arterial administration.¹

Sodium Content

Vials, pharmacy bulk packages, and ADD-Vantage vials contain ceftazidime admixed with sodium carbonate to facilitate dissolution.¹ ²¹⁷ ²³³ These preparations contain approximately 54 mg (2.3 mEq) of sodium per g of ceftazidime.¹ ²¹⁷ ²³³

Patients with Diabetes

Like other dextrose-containing solutions, use Duplex drug delivery system containing ceftazidime and dextrose injection with caution in patients with overt or known subclinical diabetes mellitus or in patients with carbohydrate intolerance for any reason.²⁵¹

Specific Populations

Pregnancy

Category B.¹

Lactation

Distributed into milk in low concentrations; use with caution.¹

Pediatric Use

To avoid unintentional overdosage, do not use ceftazidime available in Duplex containers in pediatric patients who require less than entire 1- or 2-g dose in the container.²⁵¹

Geriatric Use

No overall differences in safety and efficacy in those ≥65 years of age compared with younger adults, but the possibility of increased sensitivity in some geriatric individuals cannot be ruled out.¹

Substantially eliminated by kidneys; risk of toxicity may be greater in those with impaired renal function.¹ Select dosage with caution and assess renal function periodically because of age-related decreases in renal function.¹ (See Renal Impairment under Dosage and Administration.)

Hepatic Impairment

Pharmacokinetics not affected.¹

Renal Impairment

Possible decreased clearance and increased serum half-life.¹

Neurotoxicity reported in some patients with renal impairment who received dosage inappropriately high for their renal status.¹ (See Neurotoxicity under Cautions.)

Dosage adjustments necessary in patients with Cl_cr ≤50 mL/minute.¹ See Renal Impairment under Dosage and Administration.

Common Adverse Effects

GI effects, hypersensitivity reactions, local reactions at IV injection sites.¹

Interactions for Ceftazidime

Specific Drugs and Laboratory Tests

Drug or Test	Interaction	Comments
Aminoglycosides	Nephrotoxicity reported with concomitant use of some cephalosporins and aminoglycosides¹ ²⁰⁹ ²¹⁷ In vitro evidence of additive or synergistic antibacterial activity against Pseudomonas and Enterobacteriaceae¹ ⁵⁰ ⁶³ ⁹⁰ ¹⁴⁷ ¹⁸⁶ ¹⁸⁷ ¹⁹¹ ²¹⁷	Carefully monitor renal function, especially if high aminoglycoside dosage is used or if therapy is prolonged¹ ²¹⁷
Chloramphenicol	In vitro evidence of antagonism against gram-negative bacilli¹ ²⁷⁰ ²⁷¹ ²⁷² ²⁷³ ²⁷⁴	Avoid concomitant use¹ ²⁷⁴
Probenecid	No appreciable effect on pharmacokinetics of ceftazidime¹ ⁵ ¹⁰ ²⁴ ⁵⁰ ¹³⁰ ¹⁴⁷ ¹⁶⁴ ²¹⁷
Tests for glucose	Possible false-positive reactions in urine glucose tests using Clinitest, Benedict’s solution, or Fehling’s solution¹ ¹⁷³ ^a	Use glucose tests based on enzymatic glucose oxidase reactions (e.g., Clinistix, Tes-Tape)¹ ¹⁷³ ^a

Ceftazidime Pharmacokinetics

Absorption

Bioavailability

Not absorbed from GI tract; must be given parenterally.³ ⁵⁰

Following IM administration, peak serum concentrations attained in approximately 1 hour.¹ ⁶ ¹² ²¹⁷ May be absorbed more slowly in women than in men following IM injection into the gluteus maximus or vastus lateralis.⁶ In women, peak serum concentrations may be lower following IM injection into the gluteus maximus than into the vastus lateralis.⁶

In patients with end-stage chronic renal failure who receive a single dose of the drug via an intraperitoneal catheter, peak serum concentrations attained 2.75 hours after the dose.²⁷

Distribution

Extent

Widely distributed into body tissues and fluids including the gallbladder,²⁴ ²³⁴ ²⁵⁵ bone,¹ ³ ²³ ¹⁴⁷ ²⁰³ ²¹⁷ ²²⁰ bile,¹ ³ ¹⁰ ¹¹ ¹⁸ ²⁴ ⁴⁹ ⁵⁰ ¹⁴⁷ ²⁰³ ²¹⁷ ²⁵⁵ skeletal muscle,¹ ³ ²³ ⁵⁰ ²⁰³ ²¹⁷ ²³⁴ prostatic tissue,²¹ ²¹⁷ ²³⁴ endometrium,²⁵ myometrium,¹ ³ ²⁵ ²¹⁷ ²³⁴ heart,¹ ³ ²³ ⁵⁰ ²⁰³ ²¹⁷ skin,¹ ³ ²³ ⁵⁰ ²¹⁷ ²³⁴ adipose tissue,²³ ⁵⁰ ²³⁴ aqueous humor,¹ ³ ¹⁶ ²² ¹⁴⁷ ²⁰³ ²¹⁷ and sputum,¹ ³ ²⁸ ³⁰ ⁴⁹ ¹⁴⁷ ¹⁵⁴ ²⁰³ ²¹⁷ and pleural,²² ²⁰³ peritoneal,¹ ³ ¹⁵ ⁵⁰ ¹⁶⁶ ¹⁶⁷ ²¹⁷ synovial,¹ ³ ²¹⁷ ascitic,¹⁶⁰ ¹⁶⁶ lymphatic,¹ ³ ²² ²¹⁷ and blister¹ ³ ²² ¹⁶⁵ ²¹⁷ fluids.

Generally diffuses into CSF following IV administration;¹ ¹¹ ¹³ ¹⁹ ²⁰ ²² ⁵⁰ ¹⁴⁷ ¹⁵⁸ ²¹⁷ ²²³ ²²⁴ ²²⁶ CSF concentrations higher in patients with inflamed meninges than in those with uninflamed meninges.¹⁰ ¹³ ¹⁹ ²⁰ ²² ⁵⁰ ¹⁴⁷ ¹⁵⁸

Distributed into bile, but biliary concentrations following IM or IV administration may be lower than concurrent serum concentrations.¹⁰ ¹¹ ¹⁸ ²⁵⁵

Crosses the placenta³ ³² and is distributed into milk.¹ ³ ¹⁷ ²⁰³

Plasma Protein Binding

5–24%.¹ ⁴ ⁶ ⁸ ¹⁰ ¹¹ ⁵⁰ ¹⁴⁷ ²⁰³

Elimination

Metabolism

Not metabolized.¹ ³ ⁴ ⁹ ¹⁰ ¹¹ ¹² ²⁴ ⁵⁰ ²¹⁷

Elimination Route

Eliminated unchanged principally in urine by glomerular filtration.¹ ³ ⁷ ¹⁰ ¹¹ ²⁴ ⁴⁷ ⁵⁰ ²⁰³ ²¹⁷

80–90% of a dose eliminated in urine within 24 hours.¹ ¹² ²⁴ ¹⁶¹ ¹⁶⁵ ²⁰³ ²¹⁷

Half-life

Adults with normal renal and hepatic function: distribution half-life 0.1–0.6 hours and elimination half-life 1.4–2 hours.¹ ⁴ ⁵ ⁶ ⁷ ²⁴ ³⁶ ¹⁶¹ ¹⁶⁶ ²⁰³ ²¹⁷

Neonates: 2.2–4.7 hours.³⁴ ³⁵ ¹⁴⁷ ²²⁶

Children 1–12 months of age: 2 hours.¹⁵⁵

Special Populations

Patients with impaired hepatic function: serum half-life only slightly prolonged.¹ ²⁶ ¹⁶⁶ ²¹⁷

Patients with impaired renal function: serum concentrations higher and serum half-life prolonged.¹ ⁹ ²⁴ ³⁷ ¹⁵³ ¹⁵⁹ ¹⁶¹ ¹⁶² ²¹⁷ Serum half-life ranges from 9.4–10.3 hours in those with Cl_cr 13–27 mL/minute and 11–35 hours in those with Cl_cr<10 mL/minute.

Stability

Storage

Parenteral

Powder for Injection or IV Infusion

Fortaz: 15–30° C; protect from light.¹ ²¹⁷

Fortaz: Reconstituted IV solutions containing 100, 170, or 200 mg/mL prepared using sterile water and IV solutions that have been further diluted to 1–40 mg/mL in a compatible IV solution are stable for 12 hours at room temperature or 3 days under refrigeration.¹

Fortaz: Reconstituted IM solutions containing 280 mg/mL prepared using sterile or bacteriostatic water or 0.5 or 1% lidocaine hydrochloride are stable for 12 hours at room temperature or 3 days under refrigeration.¹

Tazicef: 20–25°C; protect from light.²¹⁷

Tazicef: Reconstituted IV or IM solutions containing 95, 180, or 280 mg/mL prepared using sterile water are stable for 24 hours at room temperature or 7 days when refrigerated.²¹⁷

Powder for injection and solutions may darken; does not indicate loss of potency.¹ ²¹⁷

For Injection, for IV Infusion

Fortaz TwistVial vials: 15–30°C; protect from light.¹ After reconstitution, stable for 12 hours at room temperature or 3 days under refrigeration.¹

Tazicef ADD-Vantage vials: 20–25°C; protect from light.²¹⁷ After reconstitution, stable for 24 hours at room temperature.²¹⁷

Duplex drug delivery system containing ceftazidime and dextrose injection: 20–25°C (may be exposed to 15–30°C);²⁵¹ protect from light.²⁵¹ After reconstitution (activation), use within 12 hours if stored at room temperature or within 3 days if stored in refrigerator; do not freeze. ²⁵¹

Injection (Frozen) for Infusion

-20° C or lower.¹ Thawed solution stable for 8 hours at room temperature or 3 days under refrigeration.¹

Do not refreeze after thawing.¹

Compatibility

For information on systemic interactions resulting from concomitant use, see Interactions.

Parenteral

Solution Compatibility

Less stable in sodium bicarbonate injection than in other IV solutions; sodium bicarbonate not recommended as a diluent.¹

Compatible^HID
Amino acids 5%, dextrose 25%
Dextrose 5% in sodium chloride 0.2, 0.45, or 0.9%¹
Dextrose 5 or 10% in water¹
Invert sugar 10% in water¹
Normosol M in dextrose 5%¹
Ringer’s injection¹
Ringer’s injection, lactated¹
Sodium bicarbonate 4.2%
Sodium chloride 0.9%¹
Sodium lactate (1/6) M¹

Drug Compatibility

Admixture CompatibilityHID
Compatible
Clindamycin phosphate
Fluconazole
Heparin sodium
Linezolid
Metronidazole
Potassium chloride
Incompatible
Amikacin sulfate
Aminophylline
Gentamicin sulfate
Ranitidine HCl
Variable
Ciprofloxacin

Y-Site CompatibilityHID
Compatible
Acyclovir sodium
Allopurinol sodium
Amifostine
Amikacin sulfate
Aminophylline
Anidulafungin
Aztreonam
Bivalirudin
Ciprofloxacin
Daptomycin
Dexmedetomidine HCl
Diltiazem HCl
Docetaxel
Dopamine HCl
Doxapram HCl
Enalaprilat
Epinephrine HCl
Esmolol HCl
Etoposide phosphate
Famotidine
Fenoldopam mesylate
Filgrastim
Fludarabine phosphate
Foscarnet sodium
Furosemide
Gallium nitrate
Gemcitabine HCl
Gentamicin sulfate
Granisetron HCl
Heparin sodium
Hetastarch in lactated electrolyte injection (Hextend)
Hydromorphone HCl
Insulin, regular
Ketamine HCl
Labetalol HCl
Linezolid
Melphalan HCl
Meperidine HCl
Methylprednisolone sodium succinate
Milrinone lactate
Morphine sulfate
Ondansetron HCl
Paclitaxel
Ranitidine HCl
Remifentanil HCl
Sufentanil citrate
Tacrolimus
Telavancin HCl
Teniposide
Thiotepa
Tigecycline
Tobramycin sulfate
Valproate sodium
Vinorelbine tartrate
Zidovudine
Incompatible
Acetylcysteine
Amiodarone HCl
Amphotericin B cholesteryl sulfate complex
Azithromycin
Caspofungin acetate
Doxorubicin HCl liposome injection
Erythromycin lactobionate
Idarubicin HCl
Midazolam HCl
Pemetrexed disodium
Pentamidine isethionate
Phenytoin sodium
Warfarin sodium
Variable
Cisatracurium besylate
Dobutamine HCl
Fluconazole
Nicardipine HCl
Propofol
Sargramostim
Theophylline
Vancomycin HCl

Actions and Spectrum

Based on spectrum of activity, classified as a third generation cephalosporin.¹ ⁴⁵ ⁵⁰ ⁵¹ ⁵² ⁵³ ⁵⁷ ⁵⁸ ⁵⁹ ⁶⁰ ⁶³ ¹⁴⁷ ¹⁵⁰ ^a Usually less active in vitro against susceptible staphylococci than first generation cephalosporins; has an expanded spectrum of activity against gram-negative bacteria compared with first and second generation cephalosporins.⁵⁰ ⁵² ⁵³ ⁵⁷ ⁵⁸ ⁵⁹ ⁶⁰ ⁶³ ¹⁴⁷ ¹⁵⁰ ¹⁹⁵ ¹⁹⁶ ²⁰⁰ ²⁰¹ ^a
Usually bactericidal.¹ ⁵⁰ ⁵² ⁵⁵ ⁵⁶ ⁹⁵ ¹⁴⁷ ¹⁵⁰ ²¹⁷ ^a
Like other β-lactam antibiotics, antibacterial activity results from inhibition of bacterial cell wall synthesis.¹ ³ ⁵⁰ ¹⁵⁰ ²¹⁷ ²³⁰ ^a
Spectrum of activity includes many gram-positive aerobic bacteria, some gram-negative aerobic bacteria, and some anaerobic bacteria; inactive against Chlamydia, fungi, and viruses.^a
Spectrum of activity of ceftazidime resembles that of ceftizoxime, cefotaxime, and ceftriaxone.⁵² ⁵³ ⁵⁵ ⁵⁸ ⁵⁹ ⁶³ ¹⁹⁶ ²⁰⁰ However, ceftazidime more active against Pseudomonas than most other currently available parenteral third generation cephalosporins⁵⁰ ⁵² ⁵³ ⁵⁴ ⁵⁵ ⁵⁶ ⁵⁸ ⁵⁹ ⁶⁰ ⁶² ¹⁵⁰ ¹⁹⁵ ¹⁹⁶ ²⁰⁰ ²⁰¹ and less active against anaerobes and gram-positive aerobic cocci than these drugs.⁵⁰ ⁵² ⁵³ ⁵⁵ ⁵⁸ ⁶⁰ ¹⁹⁵ ¹⁹⁶ ²⁰⁰ ²⁰¹
Gram-positive aerobes: active in vitro and in clinical infections against S. aureus (including β-lactamase-producing strains), S. pneumoniae, S. pyogenes (group A β-hemolytic streptococci), and S. agalactiae (group B streptococci).¹ ^a Oxacillin-resistant (methicillin-resistant) staphylococci and enterococci (e.g., Enterococcus faecalis) are resistant.¹ ^a
Gram-negative aerobes: active in vitro and in clinical infections against Citrobacter (including C. freundii, C. diversus), Enterobacter (including E. aerogenes, E. cloacae), E. coli, H. influenzae (including ampicillin-resistant strains), Klebsiella (including K. pneumoniae), Neisseria meningitidis, Proteus mirabilis, P. vulgaris, Pseudomonas (including Ps. aeruginosa), and Serratia.¹ ^a Also active in vitro against Acinetobacter, H. parainfluenzae, Morganella morganii, N. gonorrhoeae, Providencia (including P. rettgeri), Salmonella, Shigella, and Yersinia enterocolitica.¹
Anaerobes: active in vitro and in clinical infections against Bacteroides; many strains of B. fragilis are resistant.¹ Also active in vitro against Clostridium (except C. difficile), Peptococcus, and Peptostreptococcus.¹
Strains of staphylococci resistant to penicillinase-resistant penicillins (methicillin-resistant [oxacillin-resistant] staphylococci) should be considered resistant to ceftazidime, although results of in vitro susceptibility tests may indicate that the organisms are susceptible to the drug.²⁰⁴

Advice to Patients

Advise patients that antibacterials (including ceftazidime) should only be used to treat bacterial infections; they do not treat viral infections (e.g., the common cold).¹ ²¹⁷
Importance of completing full course of therapy, even if feeling better after a few days.¹ ²¹⁷
Advise patients that skipping doses or not completing the full course of therapy may decrease effectiveness and increase the likelihood that bacteria will develop resistance and will not be treatable with ceftazidime or other antibacterials in the future.¹ ²¹⁷
Advise patients that diarrhea is a common problem caused by anti-infectives and usually ends when the drug is discontinued.¹ ²¹⁷ Importance of contacting a clinician if watery and bloody stools (with or without stomach cramps and fever) occur during or as late as 2 months or longer after the last dose.¹ ²¹⁷
Importance of informing clinicians if an allergic reaction occurs.¹ ²¹⁷
Importance of women informing clinician if they are or plan to become pregnant or plan to breast-feed.¹ ²¹⁷
Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs.¹ ²¹⁷
Importance of informing patients of other important precautionary information.¹ ²¹⁷ (See Cautions.)

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Ceftazidime
Routes	Dosage Forms	Strengths	Brand Names	Manufacturer
Parenteral	For injection	equivalent to anhydrous ceftazidime 500 mg (with sodium carbonate)*	Ceftazidime for Injection
			Fortaz	Covis
		equivalent to anhydrous ceftazidime 1 g (with sodium carbonate)*	Ceftazidime for Injection
			Fortaz	Covis
			Tazicef	Hospira
		equivalent to anhydrous ceftazidime 2 g (with sodium carbonate)*	Ceftazidime for Injection
			Fortaz	Covis
			Tazicef	Hospira
		equivalent to anhydrous ceftazidime 6 g pharmacy bulk package (with sodium carbonate)*	Ceftazidime for Injection
			Fortaz	Covis
			Tazicef	Hospira
	For injection, for IV infusion	equivalent to anhydrous ceftazidime 1 g (with sodium carbonate)	Ceftazidime for Injection (available in dual-chambered Duplex drug delivery system with 5% dextrose injection)	B Braun
			Fortaz TwistVial	Covis
			Tazicef ADD-Vantage	Hospira
		equivalent to anhydrous ceftazidime 2 g (with sodium carbonate)	Ceftazidime for Injection (available in dual-chambered Duplex drug delivery system with 5% dextrose injection)	B Braun
			Fortaz TwistVial	Covis
			Tazicef ADD-Vantage	Hospira

Ceftazidime Sodium in Dextrose
Routes	Dosage Forms	Strengths	Brand Names	Manufacturer
Parenteral	Injection (frozen), for IV infusion	equivalent to 20 mg (of anhydrous ceftazidime) per mL (1 g) in 4.4% Dextrose	Fortaz Iso-osmotic in Dextrose Injection (Galaxy [Baxter])	Covis
		equivalent to 40 mg (of anhydrous ceftazidime) per mL (2 g) in 3.2% Dextrose	Fortaz Iso-osmotic in Dextrose Injection (Galaxy [Baxter])	Covis

† Use is not currently included in the labeling approved by the US Food and Drug Administration.

References

1. Covis Pharmaceuticals Inc. Fortaz (ceftazidime) powder for injection and injection prescribing information. Cary, SC; 2012 Apr.

3. Glaxo Inc. Product information form on Fortaz. Research Triangle Park, NC; 1985 Jan.

4. Kemmerich B, Warns H, Lode H et al. Multiple-dose pharmacokinetics of ceftazidime and its influence on fecal flora. Antimicrob Agents Chemother. 1983; 24:333-8. [IDIS 175796] [PubMed 6357074]

5. Luthy R, Blaser J, Bonetti A et al. Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime. Rev Infect Dis. 1982; 4(Suppl Nov-Dec):S581-4. [IDIS 161908] [PubMed 6296966]

6. Sommers DK, Walters L, Van Wyk M et al. Pharmacokinetics of ceftazidime in male and female volunteers. Antimicrob Agents Chemother. 1983; 23:892-6. [IDIS 172597] [PubMed 6351732]

7. Drusano GL, Standiford HC, Fitzpatrick B et al. Comparison of the pharmacokinetics of ceftazidime and moxalactam and their microbiological correlates in volunteers. Antimicrob Agents Chemother. 1984; 26:388-93. [IDIS 190368] [PubMed 6391372]

8. Warns H, Lode H, Harnoss CM et al. Multiple dose pharmacokinetics and therapeutic results with ceftazidime. J Antimicrob Chemother. 1983; 12(Suppl A):235-40. [PubMed 6352625]

9. Hoffler D, Koeppe P, Williams KJ. The pharmacokinetics of ceftazidime in normal and impaired renal function. J Antimicrob Chemother. 1983; 12(Suppl A):241-5. [PubMed 6352626]

10. Balant L, Dayer P, Auckenthaler R. Clinical pharmacokinetics of the third generation cephalosporins. Clin Pharmacokinet. 1985; 10:101-43. [IDIS 198911] [PubMed 3888488]

11. Noble JT, Barza M. Pharmacokinetic properties of the newer cephalosporins: a valid basis for drug selection? Drugs. 1985; 30:175-81.

12. Harding SM, Harper PB. The pharmacokinetic behaviour of ceftazidime in man and the relationship between serum levels and the in vitro susceptibility of clinical isolates. Infection. 1983; 11(Suppl 1):S49-53.

13. Alestig K, Olaison L, Rylander M. Ceftazidime for Pseudomonas meningitis. Lancet. 1985; 1:161-2. [PubMed 2857231]

14. Williams KJ. Ceftazidime for Pseudomonas meningitis. Lancet. 1985; 1:634. [IDIS 196875] [PubMed 2857964]

15. Wittman DH, Schassan HH. Penetration of eight β-lactam antibiotics into the peritoneal fluid: a pharmacokinetic investigation. Arch Surg. 1983; 118:205-13. [IDIS 166007] [PubMed 6849637]

16. Axelrod JL, Kochman RS, Horowitz MA et al. Ceftazidime concentrations in human aqueous humor. Arch Ophthalmol. 1984; 102:923-5. [IDIS 186293] [PubMed 6375645]

17. Blanco JD, Jorgensen JH, Castaneda YS et al. Ceftazidime levels in human breast milk. Antimicrob Agents Chemother. 1983; 23:479-80. [IDIS 167349] [PubMed 6342531]

18. Bouza E, Hellin T, Rodriguez-Creixems M et al. Comparison of ceftazidime concentrations in bile and serum. Antimicrob Agents Chemother. 1983; 24:104-6. [IDIS 173444] [PubMed 6414363]

19. Modai J, Vittecoq D, Decazes JM et al. Penetration of ceftazidime into cerebrospinal fluid of patients with bacterial meningitis. Antimicrob Agents Chemother. 1983; 24:126-8. [IDIS 173446] [PubMed 6354077]

20. Fong IW, Tomkins KB. Penetration of ceftazidime into the cerebrospinal fluid of patients with and without evidence of meningeal inflammation. Antimicrob Agents Chemother. 1984; 26:115-6. [IDIS 187637] [PubMed 6383206]

21. Abbas AM, Taylor MC, Da Silva C et al. Penetration of ceftazidime into the human prostate gland following intravenous injection. J Antimicrob Chemother. 1985; 15:119-21. [PubMed 3882653]

22. Walstad RA, Hellum KB, Blika S et al. Pharmacokinetics and tissue penetration of ceftazidime: studies on lymph, aqueous humour, skin blister, cerebrospinal and pleural fluid. J Antimicrob Chemother. 1983; 12(Suppl A):275-82. [PubMed 6352632]

23. Adam D, Reichart B, Williams KJ. Penetration of ceftazidime into human tissue in patients undergoing cardiac surgery. J Antimicrob Chemother. 1983; 12(Suppl A):269-73. [PubMed 6352630]

24. Saito A. Studies on absorption, distribution, metabolism and excretion of ceftazidime in Japan. J Antimicrob Chemother. 1983; 12(Suppl A):255-62. [PubMed 6352628]

25. Daschner FD, Petersen EE, Just HM et al. Penetration of ceftazidime into serum, myometrium, endometrium, salpinges and subcutaneous tissue. J Antimicrob Chemother. 1983; 12(Suppl A):247-9. [PubMed 6352627]

26. Pasko MT, Beam TR, Spooner JA et al. Safety and pharmacokinetics of ceftazidime in patients with chronic hepatic dysfunction. J Antimicrob Chemother. 1985; 15:365-74. [PubMed 3888944]

27. Tourkantonis A, Nicolaidis P. Pharmacokinetics of ceftazidime in patients undergoing peritoneal dialysis. J Antimicrob Chemother. 1983; 12(Suppl A):263-7. [PubMed 6352629]

28. Strandvik B, Malmborg AS, Alfredson H et al. Clinical results and pharmacokinetics of ceftazidime treatment in patients with cystic fibrosis. J Antimicrob Chemother. 1983; 12(Suppl A):283-7. [PubMed 6352633]

29. Drusano GL, Joshi J, Forrest A et al. Pharmacokinetics of ceftazidime, alone or in combination with piperacillin or tobramycin, in the sera of cancer patients. Antimicrob Agents Chemother. 1985; 27:605-7. [IDIS 198588] [PubMed 3890730]

30. Turner A, Pedler SJ, Carswell F et al. Serum and sputum concentrations of ceftazidime in patients with cystic fibrosis. J Antimicrob Chemother. 1984; 14:521-7. [PubMed 6392281]

31. Garcia I, Fainstein V, Smith RG et al. Multiple-dose pharmacokinetics of ceftazidime in cancer patients. Antimicrob Agents Chemother. 1983; 24:141-4. [IDIS 174901] [PubMed 6357067]

32. Giamarellou H, Gazis J, Petrikkos G et al. A study of cefoxitin, moxalactam, and ceftazidime kinetics in pregnancy. Am J Obstet Gynecol. 1983; 147:914-9. [IDIS 179400] [PubMed 6359888]

33. Mulhall A, de Louvois J. The pharmacokinetics and safety of ceftazidime in the neonate. J Antimicrob Chemother. 1985; 15:97-103. [PubMed 3882658]

34. McCracken GH, Threlkeld N, Thomas ML. Pharmacokinetics of ceftazidime in newborn infants. Antimicrob Agents Chemother. 1984; 26:583-4. [IDIS 193537] [PubMed 6393862]

35. Boccazzi A, Rizzo M, Caccamo ML et al. Comparison of the concentrations of ceftazidime in the serum of newborn infants after intravenous and intramuscular administration. Antimicrob Agents Chemother. 1983; 24:955-6. [IDIS 179243] [PubMed 6362562]

36. Leeder JS, Spino M, Tesoro AM et al. High-pressure liquid chromatographic analysis of ceftazidime in serum and urine. Antimicrob Agents Chemother. 1983; 24:720-4. [IDIS 179028] [PubMed 6362554]

37. Alestig K, Trollfors B, Andersson R et al. Ceftazidime and renal function. J Antimicrob Chemother. 1984; 13:177-81. [PubMed 6423614]

38. Prinsloo JG, Delport SD, Moncrieff J et al. Pharmacokinetics of ceftazidime in premature, newborn and young infants. S Afr Med J. 1984; 65:809-11. [IDIS 188725] [PubMed 6374925]

39. Narang PK, Hunter JR. Is renal function the only determinant in the elimination of ceftazidime? Rev Infect Dis. 1984; 6:732-5. (IDIS 191149)

40. Kroll MH, Koch TR, Drusano G et al. Lack of interference with creatinine assays by four cephalosporin-like antibiotics. Am J Clin Pathol. 1984; 82:214-6. [IDIS 188979] [PubMed 6087652]

41. Guay DR, Meatherall RC, Macaulay PA. Interference of selected second- and third-generation cephalosporins with creatinine determination. Am J Hosp Pharm. 1983; 40:435-8. [IDIS 166846] [PubMed 6846351]

42. LeBel M, Paone RP, Lewis GP. Lack of interference of five new beta-lactam antibiotics with serum creatinine determination. Drug Intell Clin Pharm. 1983; 17:908-10. [IDIS 182429] [PubMed 6317326]

43. Mondorg AW, Heynold FT, Scherberich JE et al. Assessment of the nephrotoxic potential of ceftazidime and a ceftazidime/tobramycin combination in volunteers. Infection. 1983; 11(Suppl 1):S57-62. [PubMed 6131873]

44. Foord RD. Ceftazidime: aspects of efficacy and tolerance. J Antimicrob Chemother. 1983; 12(Suppl A):399-403. [PubMed 6352651]

45. Neu HC. Relation of structural properties of beta-lactam antibiotics to antibacterial activity. Am J Med. 1985; 79(Suppl 2A):2-13.

46. Rodriguez WJ, Khan WN, Gold B et al. Ceftazidime in the treatment of meningitis in infants and children over one month of age. Am J Med. 1985; 79(Suppl 2A):52-5. [IDIS 204118] [PubMed 3895918]

47. Norrby SR. Role of cephalosporins in the treatment of bacterial meningitis in adults: overview with special emphasis on ceftazidime. Am J Med. 1985; 79(Suppl 2A):56-61. [IDIS 204119] [PubMed 3895919]

48. Meyers BR. Comparative toxicities of third-generation cephalosporins. Am J Med. 1985; 79(Suppl 2A):96-103. [IDIS 204124] [PubMed 4025384]

49. Gozzard DI, Geddes AM, Farrell ID et al. Ceftazidime: a new extended-spectrum cephalosporin. Lancet. 1982; 1:1152-6. [IDIS 150434] [PubMed 6122940]

50. Richards DM, Brogden RN. Ceftazidime: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1985; 29:105-61. [IDIS 198204] [PubMed 3884319]

51. Garzone P, Lyon J, Yu VL. Third-generation and investigational cephalosporins: I. Structure-activity relationships and pharmacokinetic review. Drug Intell Clin Pharm. 1983; 17:507-15. [IDIS 173270] [PubMed 6347596]

52. Thornsberry C. Review of in vitro activity of third-generation cephalosporins and other newer beta-lactam antibiotics against clinically important bacteria. Am J Med. 1985; 79(Suppl 2A):14-30. [IDIS 204113] [PubMed 3927723]

53. Knothe H, Dette GA. The current state of cephalosporin antibiotics: microbiological aspects. Infection. 1983; 11(Suppl 1):S12-5. [PubMed 6601063]

54. Neu HC. Structure-activity relations of new β-lactam compounds and in vitro activity against common bacteria. Rev Infect Dis. 1983; 5(Suppl 2):S319-36. [IDIS 171036] [PubMed 6342103]

55. Jones RN, Barry AL, Thornsberry C et al. Ceftazidime, a pseudomonas-active cephalosporin: in vitro antimicrobial activity evaluation including recommendations for disc diffusion susceptibility tests. J Antimicrob Chemother. 1981; 8(Suppl B):187-211. [PubMed 19802985]

56. Harper PB. In vitro properties of ceftazidime, a highly active broad-spectrum cephalosporin with antipseudomonal activity. Clin Ther. 1984; 6:411-24. [PubMed 6432324]

57. Reeves DS, Holt HA, Bywater MJ. Comparative activity in vitro of ceftazidime and nine other antibacterial agents. Infection. 1983; 11(Suppl 1):S3-11. [PubMed 6339414]

58. Garzone P, Lyon J, Yu VL. Third-generation and investigational cephalosporins: II. Microbiologic review and clinical summaries. Drug Intell Clin Pharm. 1983; 17:615-22. [IDIS 174601] [PubMed 6311502]

59. Corser CA, Day GJ, Humble MW et al. Third-generation cephalosporins: comparative antibacterial activity against routine clinical isolates. N Z Med J. 1982; 95:414-6. [IDIS 156142] [PubMed 6810246]

60. Fass RJ. Comparative in vitro activities of third-generation cephalosporins. Arch Intern Med. 1983; 143:1743-5. [IDIS 175434] [PubMed 6615095]

61. Appelbaum PC, Tamim J, Pankuch GA et al. Susceptibility of 324 nonfermentative gram-negative rods to 6 cephalosporins and azthreonam. Chemotherapy. 1983; 29:337-44. [IDIS 175165] [PubMed 6311492]

62. Livermore DM, Williams RJ, Williams JD. Comparison of the β-lactamase stability and the in-vitro activity of cefoperazone, cefotaxime, cefsulodin, ceftazidime, moxalactam and ceftriaxone against Pseudomonas aeruginosa. J Antimicrob Chemother. 1981; 8:323-31.

63. Neu HC, Labthavikul P. Antibacterial activity and β-lactamase stability of ceftazidime, an aminothiazolyl cephalosporin potentially active against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1982; 21:11-8. (IDIS 143683)

64. Bustamante CI, Drusano GL, Tatem BA et al. Postantibiotic effect of imipenem on Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1984; 26:678-82. (IDIS 194078)

65. Eng RH, Smith SM, Cherubin C. Inoculum effect of new β-lactam antibiotics on Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1984; 26:42-7. (IDIS 187629).

66. Laethem YV, Lagast H, Klastersky J. Serum bactericidal activity of ceftazidime and cefoperazone alone or in combination with amikacin against Pseudomonas aeruginosa and Klebsiella pneumoniae. Antimicrob Agents Chemother. 1983; 23:435-9. (IDIS 167345)

67. Rudrik JT, Cavalieri SJ, Britt EM. In vitro activities of enoxacin and 17 other antimicrobial agents against multiply resistant, gram-negative bacteria. Antimicrob Agents Chemother. 1984; 26:97-100. [IDIS 187633] [PubMed 6591853]

68. Khan MY, Gruninger RP, Nelson SM et al. Comparative in vitro activity of cefodizime, ceftazidime, aztreonam, and other selected antimicrobial agents against Neisseria gonorrhoeae. Antimicrob Agents Chemother. 1983; 23:477-8. (IDIS 167348)

69. Goossens H, Vanhoof R, Grados O et al. Ceftazidime activity on multiresistant Salmonella. Lancet. 1982; 2:769-70. Letter. (IDIS 158994)

70. Solomkin JS, Mazuski JE, Bradley JS et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis. 2010; 50:133-64. [PubMed 20034345]

71. Liebowitz LD, Ballard RC, Koornhof HJ. In vitro susceptibility and cross-resistance of South African isolates of Neisseria gonorrhoeae to 14 antimicrobial agents. Antimicrob Agents Chemother. 1982; 22:598-603. [IDIS 159404] [PubMed 6817704]

72. Hall WH, Opfer BJ. Influence of inoculum size on comparative susceptibilities of penicillinase-positive and -negative Neisseria gonorrhoeae to 31 antimicrobial agents. Antimicrob Agents Chemother. 1984; 26:192-5. [IDIS 189066] [PubMed 6435514]

73. Nasu M, Maskell JP, Williams RJ et al. In vitro activity of MK0787 (N-formimidoyl thienamycin) and other beta-lactam compounds against Bacteroides spp. Antimicrob Agents Chemother. 1981; 20:433-6. [IDIS 139332] [PubMed 6282191]

74. Jacobs MR, Kelly F, Speck WT. Susceptibility of group B streptococci to 16 β-lactam antibiotics, including new penicillin and cephalosporin derivatives. Antimicrob Agents Chemother. 1982; 22:897-900. [IDIS 160709] [PubMed 6758692]

75. Scribner RK, Marks MI, Weber A et al. Yersinia enterocolitica: comparative in vitro activities of seven new β-lactam antibiotics. Antimicrob Agents Chemother. 1982; 22:140-1. [IDIS 153527] [PubMed 7125625]

76. Hornstein MJ, Jupeau AM, Scavizzi MR et al. In vitro susceptibilities of 126 clinical isolates of Yersinia enterocolitica to 21 β-lactam antibiotics. Antimicrob Agents Chemother. 1985; 27:806-11. [IDIS 200508] [PubMed 2990327]

77. Laferriere C, Marks MI, Welch DF. Effect of inoculum size on Haemophilus influenzae type b susceptibility to new and conventional antibiotics. Antimicrob Agents Chemother. 1983; 24:287-9. [IDIS 174917] [PubMed 6605716]

78. Goldstein EJ, Citron DM. Susceptibility of Eikenella corrodens to penicillin, apalcillin, and twelve new cephalosporins. Antimicrob Agents Chemother. 1984; 26:947-8. [IDIS 194045] [PubMed 6395802]

79. Piot P, Van Dyck E, Colaert J. In vitro activity of ceftazidime (GR 20263) and other β-lactam antibiotics against Haemophilus influenzae. Infection. 1983; 11(Suppl 1):S32-4.

80. Muytjens HL, Heessen FW. In vitro activities of thirteen β-lactam antibiotics against Chlamydia trachomatis. Antimicrob Agents Chemother. 1982; 22:520-1. (IDIS 157302)

81. Denys GA, Jerris RC, Swenson JM et al. Susceptibility of Propionibacterium acnes clinical isolates to 22 antimicrobial agents. Antimicrob Agents Chemother. 1983; 23:335-7. [IDIS 166100] [PubMed 6838191]

82. Chattopadhyay B, Hall I, Curnow SR. Ceftazidime (GR 20263), a new cephalosporin derivative with excellent activity against Pseudomonas and Enterobacteriaceae. J Antimicrob Chemother. 1981; 8:491-3. [PubMed 6801002]

83. Alvarez S, Jones M, Holtsclaw-Berk S et al. In vitro susceptibilities and β-lactamase production of 53 clinical isolates of Branhamella catarrhalis. Antimicrob Agents Chemother. 1985; 27:646-7. (IDIS 198592)

84. Greenwood D, Eley A. Comparative antipseudomonal activity of some newer β-lactam agents. Antimicrob Agents Chemother. 1982; 21:204-9. [IDIS 146648] [PubMed 6803664]

85. Smalley DL, Hansen VR, Baselski VS. Susceptibility of Pseudomonas paucimobilis to 24 antimicrobial agents. Antimicrob Agents Chemother. 1983; 23:161-2. [IDIS 164460] [PubMed 6600908]

86. Grimm H. Criteria for the assessment of susceptibility to ceftazidime using the disc diffusion procedure. Infection. 1983; 11(Suppl 1):S35-8. [PubMed 6339416]

87. Sykes RB, Bush K. Interaction of new cephalosporins with β-lactamases and β-lactamase-producing gram-negative bacilli. Rev Infect Dis. 1983; 5(Suppl 2):S356-66.

88. Simpson IN, Plested SJ, Harper PB. Investigation of the β-lactamase stability of ceftazidime and eight other new cephalosporin antibiotics. J Antimicrob Chemother. 1982; 9:357-68. [PubMed 7047482]

89. Van Landuyt HW, Denolf BL, Pyckavet M et al. The in vitro activity of ceftazidime against resistant clinical isolates. Infection. 1983; 11(Suppl 1):S23-7. [PubMed 6299967]

90. Hooton TM, Blair AD, Turck M et al. Synergism at clinically attainable concentrations of aminoglycoside and β-lactam antibiotics. Antimicrob Agents Chemother. 1984; 26:535-8. [IDIS 193530] [PubMed 6517544]

91. Wise R, Andres JM, Danks G. Comparison of in vitro activity of FCE 22101, a new penem, with those of other β-lactam antibiotics. Antimicrob Agents Chemother. 1983; 24:909-14. [IDIS 179237] [PubMed 6607032]

92. Muytjens HL, Van der Ros-Van de Repe J. Comparative activities of 13 β-lactam antibiotics. Antimicrob Agents Chemother. 1982; 21:925-34. [IDIS 151717] [PubMed 7114839]

93. Vuye A, Pijck J. In vitro antibacterial activity of BMY-28142, a new extended-spectrum cephalosporin. Antimicrob Agents Chemother. 1985; 27:574-7. [IDIS 198582] [PubMed 3859244]

94. Toda M, Arao N, Nohara C et al. In vitro studies on the antibacterial activities of YM-13115, a new broad-spectrum cephalosporin. Antimicrob Agents Chemother. 1985; 27:565-9. [IDIS 198581] [PubMed 3890729]

95. Tsuji A, Maniatis A, Bertram MA et al. In vitro activity of BMY-28142 in comparison with those of other β-lactam antimicrobial agents. Antimicrob Agents Chemother. 1985; 27:515-9. [IDIS 198575] [PubMed 3839120]

96. Une T, Otani T, Sato M et al. In vitro and in vivo activities of DN-9550, a new broad-spectrum cephalosporin. Antimicrob Agents Chemother. 1985; 27:473-8. [IDIS 198567] [PubMed 3873898]

97. Neu HC, Labthavikul P. In vitro activity and β-lactamase stability of monobactam, SQ 26,917, compared with those of azthreonam and other agents. Antimicrob Agents Chemother. 1983; 24:227-32. [IDIS 174910] [PubMed 6605715]

98. Wise R, Andrews JM, Edwards LJ. In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents. Antimicrob Agents Chemother. 1983; 23:559-64. [IDIS 170010] [PubMed 6222695]

99. Neu HC, Labthavikul P. In vitro antibacterial activity and β-lactamase stability of E-0702, a new cephalosporin. Antimicrob Agents Chemother. 1983; 24:313-20. [IDIS 175794] [PubMed 6605718]

100. Strandberg DA, Jorgensen JH, Drutz DJ. Activities of aztreonam and new cephalosporins against infrequently isolated gram-negative bacilli. Antimicrob Agents Chemother. 1983; 24:282-6. [IDIS 174916] [PubMed 6685453]

101. Neu HC, Labthavikul P. In vitro activity and β-lactamase stability of U-63196E, a novel cephalosporin. Antimicrob Agents Chemother. 1983; 24:375-82. [IDIS 175800] [PubMed 6605719]

102. Rapp RP, Young B, Foster TS et al. Ceftazidime versus tobramycin/ticarcillin in treating hospital acquired pneumonia and bacteremia. Pharmacotherapy. 1984; 4:211-5. [IDIS 393514] [PubMed 6384945]

103. Butler JK. Microbiology, pharmacology and clinical activity of ceftazidime. Drugs Exp Clin Res. 1983; 9:9-17.

104. Flandry FC, Green G, Seago R et al. Ceftazidime as single-entity therapy for osteomyelitis and infections of skin and skin structures. Curr Ther Res Clin Exp. 1985; 37:1014-29.

105. Peirce TH, Vig SJ, Ingram PM. Ceftazidime in the treatment of lower respiratory tract infection. J Antimicrob Chemother. 1983; 12(Suppl A):21-5. [PubMed 6352621]

106. Frimodt-Moller PC, Madsen PO. Ceftazidime, a new cephalosporin in the treatment of complicated urinary tract infections: a comparative study with tobramycin. J Urol. 1983; 130:796-7. [IDIS 176695] [PubMed 6350625]

107. Gooch WM, Swensen E. Use of ceftazidime in the management of bacterial cellulitis in infants and children. Curr Ther Res Clin Exp. 1985; 37:3-8.

108. Reed MD, O'Brien CA, Aronoff SC et al. Ceftazidime as initial therapy for suspected bacterial infections in hospitalized pediatric patients. Antimicrob Agents Chemother. 1984; 26:318-21. [IDIS 190361] [PubMed 6391368]

109. Blanco JD, Gibbs RS, Duff P et al. Randomized comparison of ceftazidime versus clindamycin-tobramycin in the treatment of obstetrical and gynecological infections. Antimicrob Agents Chemother. 1983; 24:500-4. [IDIS 177498] [PubMed 6360038]

110. Roos J. Ceftazidime: a questionable alternative to the aminoglycosides. Lancet. 1982; 2:551. [IDIS 155953] [PubMed 6125698]

111. Hudson SJ, Ingham HR. Ceftazidime for Pseudomonas meningitis. Lancet. 1985; 1:464.

112. Williams KJ, Foord RD. Ceftazidime for Pseudomonas meningitis. Lancet. 1985; 1:464.

113. Childs SJ, Wells WG, Chubb JM. Ceftazidime, an open randomized comparison of 3 dosages for genitourinary infections. J Urol. 1983; 130:495-7. [IDIS 175772] [PubMed 6350616]

114. Lerner SA, Dudek EJ, Boisvert WE et al. Effect of highly potent antipseudomonal β-lactam agents alone and in combination with aminoglycosides against Pseudomonas aeruginosa. Rev Infect Dis. 1984; 6(Suppl 3):S678-88. (IDIS 191958)

115. Clumeck N, Laethem YV, Gordts B et al. Use of ceftazidime in the therapy of serious infections, including those due to multiresistant organisms. Antimicrob Agents Chemother. 1983; 24:176-80. [IDIS 174906] [PubMed 6357068]

116. Bergin CJ, Phillips P, Chan RM et al. Treatment of pseudomonas and serratia infections with ceftazidime. J Antimicrob Chemother. 1985; 15:613-21. [PubMed 3924882]

117. Eron LJ, Goldenberg RI, Park CH et al. Ceftazidime therapy of serious bacterial infections. Antimicrob Agents Chemother. 1983; 23:236-41. [IDIS 166088] [PubMed 6340601]

118. Maslo MJ, Rosenberg A, Pollock AA et al. Ceftazidime therapy of infections caused by Enterobacteriaceae and Pseudomonas aeruginosa. J Antimicrob Chemother. 1983; 12(Suppl A):213-7.

119. Scully BE, Neu HC. Clinical efficacy of ceftazidime: treatment of serious infection due to multiresistant Pseudomonas and other gram-negative bacteria. Arch Intern Med. 1984; 144:57-62. [IDIS 179964] [PubMed 6419690]

120. Pottage JC, Karakusis PH, Fliegelman RM et al. Ceftazidime in the therapy of serious gram-negative bacillary infections. J Antimicrob Chemother. 1983; 12(Suppl A):223-8. [PubMed 6352623]

121. Bodey GP. Antibiotics in patients with neutropenia. Arch Intern Med. 1984; 144:1845-51. [IDIS 189834] [PubMed 6477006]

122. Williamson PJ, Darbyshire PJ, Mott MG et al. Ceftazidime and tobramycin in the treatment of febrile, immunosuppressed children. J Antimicrob Chemother. 1984; 14:671. [PubMed 6394573]

123. Clough JV, Farrell ID, Wood MJ et al. Ceftazidime plus mezlocillin as initial antibiotic therapy in febrile neutropenic patients with haematological malignancy. J Antimicrob Chemother. 1985; 15:353-63. [PubMed 3888943]

124. Morgan G, Duerden BI, Lilleyman JS. Ceftazidime as a single agent in the management of children with fever and neutropenia. J Antimicrob Chemother. 1983; 12(Suppl A):347-51. [PubMed 6352641]

125. Nelson JD. Management of acute pulmonary exacerbations in cystic fibrosis: a critical appraisal. J Pediatr. 1985; 106:1030-4. [IDIS 200973] [PubMed 3889252]

126. Heilesen AM, Permin H, Koch C et al. Treatment of chronic Pseudomonas aeruginosa infection in cystic fibrosis patients with ceftazidime and tobramycin. Scand J Infect Dis. 1983; 15:271-6. [PubMed 6417770]

127. Anon. Antibiotic dosage in cystic fibrosis. Lancet. 1985; 1:1020-1. [PubMed 2859469]

128. Gordts B, Dab I, Butzler JP. Ceftazidime in cystic fibrosis. Lancet. 1982; 1:1355. [IDIS 151432] [PubMed 6123654]

129. Padoan R, Brienza A, Crossignani RM et al. Ceftazidime in treatment of acute pulmonary exacerbations in patients with cystic fibrosis. J Pediatr. 1983; 103:320-4. [IDIS 174092] [PubMed 6348228]

130. Kercsmar CM, Stern RC, Reed MD et al. Ceftazidime in cystic fibrosis: pharmacokinetics and therapeutic response. J Antimicrob Chemother. 1983; 12(Suppl A):289-95. [PubMed 6352634]

131. So SY, Chau PY, Leung YK et al. Successful treatment of melioidosis caused by a multiresistant strain in an immunocompromised host with third generation cephalosporins. Am Rev Respir Dis. 1983; 127:850-4.

132. Norrby SR. Ceftazidime in clinical practice—a summary. J Antimicrob Chemother. 1983; 12(Suppl A):405-8. [PubMed 6352652]

133. Gold R, Jin E, Levison H et al. Ceftazidime alone and in combination in patients with cystic fibrosis: lack of efficacy in treatment of severe respiratory infections caused by Pseudomonas cepacia. J Antimicrob Chemother. 1983; 12(Suppl A):331-6. [PubMed 6352638]

134. Mastella G, Agostini M, Barlocco G et al. Alternative antibiotics for the treatment of pseudomonas infections in cystic fibrosis. J Antimicrob Chemother. 1983; 12(Suppl A):297-311. [PubMed 6311788]

135. Clumeck N, Gordts B, Dab I et al. Ceftazidime as a single agent in the treatment of severe Pseudomonas aeruginosa infections. J Antimicrob Chemother. 1983; 12(Suppl A):207-11. [PubMed 6352620]

136. Eron LJ, Park CH, Hixon DL et al. Ceftazidime in patients with pseudomonas infections. J Antimicrob Chemother. 1983; 12(Suppl A):161-9. [PubMed 6225762]

137. Francioli P, Clement M, Geroulanos S et al. Ceftazidime in severe infections: a Swiss multicentre study. J Antimicrob Chemother. 1983; 12(Suppl A):139-46. [PubMed 6225761]

138. Fainstein V, Bodey GP, Elting L et al. A randomized study of ceftazidime compared to ceftazidime and tobramycin for the treatment of infections in cancer patients. J Antimicrob Chemother. 1983; 12(Suppl A):101-10. [PubMed 6352612]

139. de Pauw BE, Kauw F, Muytjens H et al. Randomized study of ceftazidime versus gentamicin plus cefotaxime for infections in severe granulocytopenic patients. J Antimicrob Chemother. 1983: 12(Suppl A):93-9.

140. Ramphal R, Kramer BS, Rand KH et al. Early results of a comparative trial of ceftazidime versus cephalothin, carbenicillin and gentamicin in the treatment of febrile granulocytopenic patients. J Antimicrob Chemother. 1983; 12(Suppl A):81-8. [PubMed 6352659]

141. Madsen PO, Frimodt-Moller PC. Complicated urinary tract infections treated with ceftazidime and tobramycin: a comparative study. J Antimicrob Chemother. 1983; 12(Suppl A):77-9. [PubMed 6352658]

142. Childs SJ, Mirelman S, Wells WG. Perioperative use of ceftazidime as a prophylactic agent in transurethral surgery. J Antimicrob Chemother. 1983; 12(Suppl A):71-6. [PubMed 6311789]

143. Vetter N, Feist H, Muhar F et al. A comparative study of the efficacy of ceftazidime versus cefazolin and tobramycin in patients with acute exacerbations of chronic bronchitis. J Antimicrob Chemother. 1983: 12(Suppl A):35-9.

144. Mandell LA, Nicolle LE, Ronald AR et al. A multicentre prospective randomized trial comparing ceftazidime with cefazolin/tobramycin in the treatment of hospitalized patients with non-pneumococcal pneumonia. J Antimicrob Chemother. 1983; 12(Suppl A):9-20. [PubMed 6352661]

145. Horowitz EA, Preheim LC, Safranek TJ et al. Randomized, double-blind comparison of ceftazidime and moxalactam in complicated urinary tract infections. Antimicrob Agents Chemother. 1985; 28:299-301. [IDIS 204291] [PubMed 3914859]

146. Cone LA, Woodard DR, Stoltzman DS et al. Ceftazidime versus tobramycin-ticarcillin in the treatment of pneumonia and bacteremia. Antimicrob Agents Chemother. 1985; 28:33-6. [IDIS 203394] [PubMed 3899005]

147. Smith BR. Cefsulodin and ceftazidime, two antipseudomonal cephalosporins. Clin Pharm. 1984; 3:373-85. [IDIS 187700] [PubMed 6380902]

148. Engle JC, Lifland PW, Schleupner CJ. Comparison of ceftazidime with cefamandole for therapy of community-acquired pneumonia. Antimicrob Agents Chemother. 1985; 28:146-8. [IDIS 203412] [PubMed 3899002]

149. Kelly HW, Lovato C. Antibiotic use in cystic fibrosis. Drug Intell Clin Pharm. 1984; 18:772-83. [IDIS 190393] [PubMed 6435985]

150. Yost RL, Ramphal R. Ceftazidime review. Drug Intell Clin Pharm. 1985; 19:509-13. [IDIS 202154] [PubMed 3896712]

151. Blanco JD, Lipscomb KA. Single-dose prophylaxis in vaginal hysterectomy: a double-blind, randomized comparison of ceftazidime versus cefotaxime. Curr Ther Res Clin Exp. 1984; 36:389-93.

152. Rusconi F, Assael BM, Florioli A et al. Ceftazidime in the treatment of pediatric patients with severe urinary tract infections due to Pseudomonas spp. Antimicrob Agents Chemother. 1984; 25:395-7. [IDIS 183098] [PubMed 6372686]

153. Naber KG, Kees F, Grobecker H. Ceftazidime: pharmacokinetics in young volunteers versus elderly patients and therapeutic efficacy with complicated urinary tract infections. J Antimicrob Chemother. 1983; 12(Suppl A):41-5. [PubMed 6352653]

154. Assael BM, Boccazzi A, Caccamo ML et al. Clinical pharmacology of ceftazidime in pediatrics. J Antimicrob Chemother. 1983; 12(Suppl A):341-6. [PubMed 6352640]

155. Prinsloo JG, Delport SD, Moncrieff J et al. A preliminary pharmacokinetic study of ceftazidime in premature, new born and small infants. J Antimicrob Chemother. 1983; 12(Suppl A):361-4. [PubMed 6352645]

156. LeBel M, Barbeau G, Vallee F et al. Pharmacokinetics of ceftazidime in elderly volunteers. Antimicrob Agents Chemother. 1985; 28:713-5. [IDIS 208218] [PubMed 3911883]

157. Leeder JS, Spino M, Isles AF et al. Ceftazidime disposition in acute and stable cystic fibrosis. Clin Pharmacol Ther. 1984; 36:355-62. [IDIS 191247] [PubMed 6432400]

158. Polk RE, Mayhall CG, Tartaglione T et al. Sequential ventricular fluid concentrations of ceftazidime—report of three cases. Drug Intell Clin Pharm. 1984; 18:984-7. [IDIS 192944] [PubMed 6391885]

159. Ackerman BH, Ross J, Tofte RW et al. Effect of decreased renal function on the pharmacokinetics of ceftazidime. Antimicrob Agents Chemother. 1984; 25:785-6. [IDIS 186590] [PubMed 6378087]

160. Benoni G, Arosio E, Raimondi MG et al. Distribution of ceftazidime in ascitic fluid. Antimicrob Agents Chemother. 1984; 25:760-3. [IDIS 186585] [PubMed 6378086]

161. Leroy A, Leguy F, Borsa F et al. Pharmacokinetics of ceftazidime in normal and uremic subjects. Antimicrob Agents Chemother. 1984; 25:638-42. [IDIS 185382] [PubMed 6375562]

162. Welage LS, Schultz RW, Schentag JJ. Pharmacokinetics of ceftazidime in patients with renal insufficiency. Antimicrob Agents Chemother. 1984; 25:201-4. [IDIS 181952] [PubMed 6370127]

163. Bauernfeind A, Petermüller CH, Jungwirth R. Inactivation of cephalosporins by beta-lactamases of gram-negative rods. Infection. 1983; 11(Suppl 1):S39-43. [PubMed 6339417]

164. Luthy R, Blaser J, Bonetti A et al. Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime. Antimicrob Agents Chemother. 1981; 20:567-75. [IDIS 141468] [PubMed 6275776]

165. Armstrong GC, Wise R, Brown RM et al. Comparison of ceftazidime and cefamandole pharmacokinetics and blister fluid concentrations. Antimicrob Agents Chemother. 1981; 20:356-8. [IDIS 137578] [PubMed 7030200]

166. Benoni G, Arosio E, Raimondi MG et al. Pharmacokinetics of ceftazidime and ceftriaxone and their penetration into the ascitic fluid. J Antimicrob Chemother. 1985; 16:267-73. [PubMed 3905752]

167. Corbett CR, McFarland RJ, Spender GR et al. The penetration of ceftazidime into peritoneal fluid in patients undergoing elective abdominal surgery. J Antimicrob Chemother. 1985; 16:261-5. [PubMed 3905751]

168. . Antimicrobial prophylaxis for surgery. Treat Guidel Med Lett. 2012; 10:73-8; quiz 79-80. [PubMed 22996382]

169. Bratzler DW, Dellinger EP, Olsen KM et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health Syst Pharm. 2013; 70:195-283. [PubMed 23327981]

170. Beam TR, Pasko MT, Spooner JA et al. Lack of effect of ceftazidime on serum glucose in patients with liver disease. Clin Pharm. 1985; 4:72-4. [IDIS 195933] [PubMed 3882315]

171. Rouveix B, Lassoued K, Vittecoq D et al. Neutropenia due to β-lactamine antibodies. BMJ. 1983; 287:1832-4. [IDIS 180450] [PubMed 6423036]

172. Meatherall RC, Guay DR, Baxter H et al. Cephalosporins and urinary protein determination. Clin Chem. 1985; 31:165. [IDIS 194984] [PubMed 3965206]

173. LeBel M, Paone RP, Lewis GP. Effect of ten new β-lactam antibiotics on urine glucose test methods. Drug Intell Clin Pharm. 1984; 18:617-20. [IDIS 187103] [PubMed 6745089]

174. Chow AW, Bartlett KH. Comparative in-vitro activity of ceftazidime (GR-20263) and other β-lactamase stable cephalosporins against anaerobic bacteria. J Antimicrob Chemother. 1981; 8(Suppl B):91-5. [PubMed 19802974]

175. Labia R, Beguin-Billicoq R, Guionie M. Behaviour of ceftazidime towards β-lactamases. J Antimicrob Chemother. 1981; 8(Suppl B):141-6. [PubMed 19810176]

176. Mouton RP, Bongaerts GP, Van Gestel MH. Susceptibility of ceftazidime and other cephalosporins to a range of β-lactamases and their potential as inducing agents. J Antimicrob Chemother. 1981; 8(Suppl B):147-52. [PubMed 19802978]

177. Phillips I, Warren C, Shannon K et al. Ceftazidime: in vitro antibacterial activity and susceptibility to β-lactamases compared with that of cefotaxime, moxalactam and other β-lactam antibiotics. J Antimicrob Chemother. 1981; 8(Suppl B):23-31. [PubMed 19802967]

178. Eng RH, Cherubin C, Smith SM et al. Inoculum effect of lactam antibiotics on Enterobacteriaceae. Antimicrob Agents Chemother. 1985; 28:601-6. [PubMed 4091525]

179. Goldstein EJ, Citron DM. Comparative in vitro inhibitory and killing activity of cefpirome, ceftazidime, and cefotaxime against Pseudomonas aeruginosa, enterococci, Staphylococcus epidermidis, and methicillin-susceptible and -resistant and tolerant and nontolerant Staphylococcus aureus. Antimicrob Agents Chemother. 1985; 28:160-2.

180. LeFrock JL, Smith BR, Bihl J. Comparative in vitro evaluation of cefpimizole (U-63196E), a new antipseudomonal cephalosporin. Antimicrob Agents Chemother. 1985; 28:133-7. [IDIS 203410] [PubMed 3929676]

181. Van der Auwera P, Scorneaux B. In vitro susceptibility of Campylobacter jejuni to 27 antimicrobial agents and various combinations of β-lactams with clavulanic acid or sulbactam. Antimicrob Agents Chemother. 1985; 28:37-40. [IDIS 203395] [PubMed 2994557]

182. Larsson S, Walder MH, Cronberg SN et al. Antimicrobial susceptibilities of Listeria monocytogenes strains isolated from 1958 to 1982 in Sweden. Antimicrob Agents Chemother. 1985; 28:12-4. [IDIS 203392] [PubMed 3929675]

183. Cullmann W, Opferkuch W, Stieglitz M et al. Influence of spontaneous and inducible β-lactamase production on the antimicrobial activity of recently developed β-lactam compounds. Chemotherapy. 1984; 30:175-81. [IDIS 184675] [PubMed 6610539]

184. Digranes A, Dibb WL, Benonisen E. Ceftazidime: in vitro comparison with cephalothin, cefuroxime, and netilmicin. Chemotherapy. 1984; 30:113-8. [IDIS 182283] [PubMed 6365480]

185. Bremner DA. Azthreonam activity against gram-negative bacilli. Chemotherapy. 1984; 30:44-8. [IDIS 181893] [PubMed 6537908]

186. Rolston KV, Chandrasekar PH, LeFrock JL et al. The activity of ceftazidime, other β-lactams, and aminoglycosides against Pseudomonas aeruginosa. Chemotherapy. 1984; 30:31-4. (IDIS 181891)

187. Scribner RK, Marks MI, Weber AH et al. Activities of various β-lactams and aminoglycosides, alone and in combination, against isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. Antimicrob Agents Chemother. 1982; 21:939-43. [IDIS 151719] [PubMed 6810757]

188. Scribner RK, Wedros BC, Weber AH et al. Activities of eight new β-lactam antibiotics and seven antibiotic combinations against Neisseria meningitidis. Antimicrob Agents Chemother. 1982; 21:678-80. (IDIS 157807)

189. Wise R, Andrews JM, Hancox J. In vitro activity of cefotetan, a new cephamycin derivative, compared with that of other β-lactam compounds. Antimicrob Agents Chemother. 1982; 21:486-91. [IDIS 146374] [PubMed 6954875]

190. Fainstein V, Weaver S, Bodey GP. In vitro susceptibilities of Aeromonas hydrophila against new antibiotics. Antimicrob Agents Chemother. 1982; 22:513-4. [IDIS 157299] [PubMed 7137987]

191. Bayer AS, Eisenstadt R, Morrison JO. Enhanced in vitro bactericidal activity of amikacin or gentamicin combined with three new extended-spectrum cephalosporins against cephalothin-resistant members of the family Enterobacteriaceae. Antimicrob Agents Chemother. 1984; 25:725-8. [IDIS 186582] [PubMed 6331297]

192. Wu DH, Baltch AL, Smith RP. In vitro comparison of Pseudomonas aeruginosa isolates with various susceptibilities to aminoglycosides and ten β-lactam antibiotics. Antimicrob Agents Chemother. 1984; 25:488-90. [IDIS 184283] [PubMed 6428308]

193. Brorson JE, Bjornegard B, Trollfors B. The in-vitro activity of ceftazidime in combination with ampicillin or piperacillin. J Antimicrob Chemother. 1985; 16:407. [PubMed 4055546]

194. Wise R, Andrews JM, Edwards LJ. In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents. Antimicrob Agents Chemother. 1983; 23:559-64. [IDIS 170010] [PubMed 6222695]

195. Wise R, Andrews JM, Bedford KA. Comparison of in vitro activity of GR 20263, a novel cephalosporin derivative, with activities of other beta-lactam compounds. Antimicrob Agents Chemother. 1980; 17:884-9. [IDIS 116955] [PubMed 6772097]

196. O'Callaghan CH, Acred P, Harper PB et al. GR 20263, a new broad-spectrum cephalosporin with anti-pseudomonal activity. Antimicrob Agents Chemother. 1980; 17:876-83. [IDIS 116954] [PubMed 6994642]

197. Anon. Drugs for bacterial infections. Med Lett Treat Guid. 2010; 8:43-52.

198. Prince AS, Neu HC. Activities of new beta-lactam antibiotics against isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. Antimicrob Agents Chemother. 1981; 20:545-6. [IDIS 139343] [PubMed 6282199]

199. Bodey GP, Fainstein V, Hinkle AM. Comparative in vitro study of new cephalosporins. Antimicrob Agents Chemother. 1981; 20:226-30. [IDIS 136127] [PubMed 7283419]

200. Hamilton-Miller JM, Brumfitt W. Activity of ceftazidime (GR 20263) against nosocomially important pathogens. Antimicrob Agents Chemother. 1981; 19:1067-9. [IDIS 133233] [PubMed 7023381]

201. Verbist L. Comparison of in vitro activities of eight β-lactamase-stable cephalosporins against β-lactamase-producing gram-negative bacilli. Antimicrob Agents Chemother. 1981; 19:407-13. [IDIS 134657] [PubMed 6972728]

202. Verbist L, Verhaegen J. In vitro activity of N-formimidoyl thienamycin in comparison with cefotaxime, moxalactam, and ceftazidime. Antimicrob Agents Chemother. 1981; 19:402-6. [IDIS 134656] [PubMed 6264844]

203. Harding SM. Pharmacokinetics of the third-generation cephalosporins. Am J Med. 1985; 79(Suppl 2A):21-4. [IDIS 204114] [PubMed 4025382]

204. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; sixteenth informational supplement. CLSI document M100-S16. Wayne, PA; 2006.

205. Ettlin R, Hoigné R, Bruppacher R et al. Atopy and adverse drug reactions. Int Arch Allergy Appl Immunol. 1981; 66(Suppl 1):93-5.

206. Patterson R. Allergic reactions to drugs and biological agents. JAMA. 1982; 248:2637-45. [IDIS 160687] [PubMed 7143626]

207. Hoigné R, Hopf B, Sonntag R. Penicillins, cephalosporins and tetracyclines. In: Dukes MNG, ed. Meyler’s side effects of drugs. 9th ed. New York: Elsevier/North Holland Inc; 1980:411-22.

208. Blumer JL, Stern RC, Klinger JD et al. Ceftazidime therapy in patients with cystic fibrosis and multiply-drug-resistant Pseudomonas. Am J Med. 1985; 79(Suppl 2A):37-46.

209. Mannion JC, Bloch R, Popovich NG. Cephalosporin-aminoglycoside synergistic nephrotoxicity: fact or fiction? Drug Intell Clin Pharm. 1981; 15:248-56.

210. Lamother F, Auger F, Lacroix MJ. Effect of clavulanic acid on the activities of ten β-lactam agents against members of the Bacteroides fragilis group. Antimicrob Agents Chemother. 1984; 25:662-5. [PubMed 6732233]

211. Pizzo PA, Thaler M, Hathorn J et al. New beta-lactam antibiotics in granulocytopenic patients: new options and new questions. Am J Med. 1985; 79(Suppl 2A):75-82. [PubMed 3895922]

212. Fainstein V, Bodey GP. Single-agent therapy for infections in neutropenic cancer patients. Am J Med. 1985; 79(Suppl 2A):83-8. [IDIS 204122] [PubMed 3895923]

213. Barriere SL. Controversies in antimicrobial therapy: formulary decisions on third-generation cephalosporins. Am J Hosp Pharm. 1986; 43:625-9. [PubMed 3706317]

214. Trenholme GM, Pottage JC, Karakusis PH. Use of ceftazidime in the treatment of nosocomial lower respiratory infections. Am J Med. 1985; 79(Suppl 2A):32-6. [IDIS 204115] [PubMed 3895916]

215. Selwyn S. Applied pharmacology, adverse effects and drug interactions. In: Selwyn S, ed. The beta-lactam antibiotics: penicillins and cephalosporins in perspective. London: Hodder and Stoughton; 1980:91-126.

216. Nelson JD. Emerging role of cephalosporins in bacterial meningitis. Am J Med. 1985; 79(Suppl 2A):47-51. [IDIS 204117] [PubMed 3849260]

217. Hospira Inc. Tazicef (ceftazidime) powder for injection and injection prescribing information. Lake Forest, IL; 2007 Mar.

218. Rolfe RD, Finegold SM. Comparative in vitro activity of new beta-lactam antibiotics against anaerobic bacteria. Antimicrob Agents Chemother. 1980; 20:600-9.

219. Centers for Disease Control and Prevention. Diagnosis and management of foodborne illness. A primer for physicians. MMWR Morb Mortal Wkly Rep. 2001; 50(No. RR-2):1-69. [PubMed 11215787]

220. Leigh DA, Griggs J, Tighe CM et al. Pharmacokinetic study of ceftazidime in bone and serum of patients undergoing hip and knee arthroplasty. J Antimicrob Chemother. 1985; 16:637-42. [PubMed 3908436]

221. Furniss LD (Glaxo Inc, Research Triangle Park, NC): Personal communication; 1986 May.

222. Reviewers’ comments (personal observations).

223. Elliott TS, Ispahani P, Cowlishaw WA. Gram-negative bacillary meningitis in neonates: a glimmer of therapeutic success. J Antimicrob Chemother. 1986; 17:245-50. [PubMed 3516965]

224. Low DC, Bissenden JD, Wise R. Ceftazidime in neonatal infections. Arch Dis Child. 1985; 60:360-4. [IDIS 200584] [PubMed 3890766]

225. Kammer R (Eli Lilly and Company, Indianapolis, IN): Personal communication.

226. Blumer JL, Aronoff SC, Myers CM et al. Pharmacokinetics and cerebrospinal fluid penetration of ceftazidime in children with meningitis. Dev Pharmacol Ther. 1985; 8:219-31. [PubMed 3896704]

227. Mandell LA, Wunderink RG, Anzueto A et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007; 44 Suppl 2:S27-72. [PubMed 17278083]

228. Pizzo PA, Hathorn JW, Hiemenz J et al. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med. 1986; 315:552-8. [IDIS 219827] [PubMed 3526155]

229. Young LS. Empirical antimicrobial therapy in the neutropenic host. N Engl J Med. 1986; 315:580-1. [PubMed 3526156]

230. Klastersky J. Concept of empiric therapy with antibiotic combinations: indications and limits. Am J Med. 1986; 80(Suppl 5C):2-12. [IDIS 217459] [PubMed 3521271]

231. Lagast H, Klastersky J, Kains JP et al. Empiric antimicrobial therapy with aztreonam or ceftazidime in gram-negative septicemia. Am J Med. 1986; 80(Suppl 5C):79-84. [IDIS 217466] [PubMed 3521272]

232. Wade JC, Johnson DE, Bustamante CI. Monotherapy for empiric treatment of fever in granulocytopenic cancer patients. Am J Med. 1986; 80(Suppl 5C):85-95. [IDIS 217467] [PubMed 3521273]

233. Hospira Inc. Tazicef (ceftazidime) powder for injection pharmacy bulk package prescribing information. Lake Forest, IL; 2007 Mar.

234. Loebis LH. Tissue levels in patients after intravenous administration of ceftazidime. J Antimicrob Chemother. 1985; 16:757-61. [PubMed 3912366]

244. Kishiyam JL, Adelman DC. The cross-reactivity and immunology of β-lactam antibiotics. Drug Saf. 1994; 10:318-27. [PubMed 8018304]

245. Thompson JW, Jacobs RF. Adverse effects of newer cephalosporins: an update. Drug Saf. 1993; 9:132-42. [PubMed 8397890]

246. Reed MD, Stern RC, O'Brien CA et al. Randomized double-blind evaluation of ceftazidime dose ranging in hospitalized patients with cystic fibrosis. Antimicrob Agents Chemother. 1987; 31:698-702. [IDIS 229462] [PubMed 3111360]

247. Kramer BS, Ramphal R, Rand KH. Randomized comparison between two ceftazidime-containing regimens and cephalothin-gentamicin-carbenicillin in febrile granulocytopenic cancer patients. Antimicrob Agents Chemother. 1986; 30:64-8. [IDIS 218659] [PubMed 3530126]

248. Verhagen CS, de Pauw B, de Witte T et al. Randomized prospective study of ceftazidime versus ceftazidime plus cephalothin in empiric treatment of febrile episodes in severely neutropenic patients. Antimicrob Agents Chemother. 1987; 31:191-6. [IDIS 226543] [PubMed 3551829]

249. Hathorn JW, Rubin M, Pizzo PA. Empirical antibiotic therapy in the febrile neutropenic cancer patient: clinical efficacy and impact of monotherapy. Antimicrob Agents Chemother. 1987; 31:971-7. [PubMed 3310871]

250. Baxter Healthcare Corporation. Descriptive information on premixed frozen products. Deerfield, IL; 1992 Sep.

251. B. Braun Medical, Inc. Ceftazidime for injection USP and dextrose injection USP in Duplex container for intravenous use prescribing information. Irvine, Ca; 2012 Apr.

252. Preblud SR, Gill CJ, Campos JM. Bactericidal activities of chloramphenicol and eleven other antibiotics against Salmonella spp. Antimicrob Agents Chemother. 1984; 25:327-30. [IDIS 183088] [PubMed 6372681]

254. Committee on Infectious Diseases. Treatment of bacterial meningitis. Pediatrics. 1988; 81:904-7. [IDIS 242284] [PubMed 3368290]

255. Shiramatsu K, Hirata K, Yamada T et al. Ceftazidime concentration in gallbladder tissue and excretion in bile. Antimicrob Agents Chemother. 1988; 32:1588-9. [IDIS 246914] [PubMed 3056242]

256. Anon. Vibrio vulnificus infections associated with eating raw oysters—Los Angeles, 1996. MMWR Morb Mortal Wkly Rep. 1996; 45:621-4. [PubMed 8965788]

257. Al-Zahawi MF, Sprott MS, Hendrick DJ. Hallucinations in association with ceftazidime. BMJ. 1988; 297:858. [IDIS 246321] [PubMed 3140957]

258. Antibiotic drugs: ceftazidime sodium injection. Fed Regist. 1989; 54:40651-3.

259. Hulverson S (Baxter, Deerfield, IL): Personal Communication; 1989 Dec 15.

261. De Pauw BE, Deresinski SC, Feld R et al. Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer: a multicenter randomized trial. Ann Intern Med. 1994; 120:834-44. [IDIS 329342] [PubMed 8154643]

262. Kumamoto KS, Vukich DJ. Clinical infections of Vibrio vulnificus: a case report and review of the lieterature. Emerg Med. 1998; 16:61-6

263. Anon. Vibrio vulnificus infections associated with raw oyster consumption—Florida, 1981-1992. MMWR Morb Mortal Wkly Rep. 1993; 42:405-7. [PubMed 8497241]

264. Suputtamongkol Y, Rajchanuwong A, Chaowagul W et al. Ceftazidime vs. amoxicillin/clavulanate in the treatment of severe melioidosis. Clin Infect Dis. 1994; 19:846-53. [IDIS 339940] [PubMed 7893868]

265. Morgan Murray D, DuPont HL. Onset of life-threatening ventriculitis during ceftazidime therapy for nosocomial pneumonia due to Enterobacter cloacae. Clin Infect Dis. 1993; 17:295-6. [IDIS 318290] [PubMed 8399893]

266. White NJ, Dance DAB, Chaowagul W et al. Halving of mortality of severe melioidosis by ceftazidime. Lancet. 1989; 2:697-701. [IDIS 259319] [PubMed 2570956]

267. Sauerwein RW, Lammers JW, Horrevorts AM. Ceftazidime monotherapy for pulmonary meliodosis in a traveler returning from Thailand. Chest. 1992; 101:555-7. [IDIS 291548] [PubMed 1735289]

268. Vinks SATMM, Heijerman HGM, deJonge P et al. Photosensitivity due to ambulatory intravenous ceftazidime in cystic fibrosis patient. Lancet. 1993; 341:1221-2.

269. Baxter Healthcare Corporation. Descriptive information on premixed products. Deerfield, IL; 1994 Feb 21.

270. Brown TH, Alford RH. Antagonism by chloramphenicol of broad-spectrum β-lactam antibiotics against Klebsiella pneumoniae. Antimicrob Agents Chemother. 1984; 25:405-7. [IDIS 184272] [PubMed 6375551]

271. Asmar BI, Prainito M, Dajani AS. Antagonistic effect of chloramphenicol in combination with cefotaxime of ceftriaxone. Antimicrob Agents Chemother. 1988; 32:1375-8. [IDIS 248089] [PubMed 3195999]

272. Dance DA, Wuthiekanun V, Chaowagul W et al. Interactions in vitro between agents used to treat melioidosis. J Antimicrob Chemother. 1989; 24:311-6. [PubMed 2681117]

273. French GL, Ling TKW, Davies DP et al. Antagonism of ceftazidime by chloramphenicol in vitro and in vivo during treatment of gram negative meningitis. BMJ. 1985; 291:636-7. [IDIS 205179] [PubMed 3928061]

274. Cephalosporins interactions: chloramphenicol (Chloromycetin). In: Hansten PD, Horn JR. Drug interactions and updates. Vancouver, WA: Applied Therapeutics, Inc; 1993:210.

275. American Academy of Pediatrics. Red Book: 2012 Report of the Committee on Infectious Diseases. 29th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2012.

276. Sookpranee M, Boonma P, Susaengrat W et al. Multicenter prospective randomized trial comparing ceftazidime plus co-trimoxazole with chloramphenicol plus doxycycline and co-trimoxazole for treatment of severe melioidosis. Antimicrob Agents Chemother. 1992; 36:158-62. [IDIS 289792] [PubMed 1590682]

277. Camus C, Cartier F, Avril JL et al. Efficacy of ceftazidime in chronic melioidosis with multiple liver abscesses. Lancet. 1990; 2:628.

278. Carmeli Y, Samore MH. Comparison of treatment with imipenem vs. ceftazidime as a predisposing factor for nosocomial acquisition of Stenotrophomonas maltophilia: a historical cohort study. Clin Infect Dis. 1997; 24:1131-4. [IDIS 388558] [PubMed 9195070]

279. Cometta A, Zinner S, de Bock R et al. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother. 1995; 39:445-52. [IDIS 341972] [PubMed 7726513]

280. Cordonnier C, Herbrecht R, Pico JL et al et al. cefepime/amikacin versus ceftazidime/amikacin as empirical therapy for febrile episodes in neutropenic patients: a comparative study. Clin Infect Dis. 1997; 24:41-51. [IDIS 378942] [PubMed 8994754]

283. Ramphal R, Gucalp R, Rotstein C et al. Clinical experience with single agent and combination regimens in the management of infection in the febrile neutropenic patient. Am J Med. 1996; 100(Suppl 6A):83S-89S). [IDIS 370422] [PubMed 8678102]

284. Viscoli C. The evolution of the empirical management of fever and neutropenia in cancer patients. J Antimicrob Chemother. 1998; 41(Suppl D):65-80. [IDIS 409104] [PubMed 9688453]

285. Rolston KV. Expanding the options for risk-based therapy in febrile neutropenia. Diagn Microbiol Infect Dis. 1998; 31:411-6. [PubMed 9635917]

286. Link H, Maschmeyer G, Meyer P et al. Interventional antimicrobial therapy in febrile neutropenic patients. Ann Hematol. 1994; 69:231-43. [PubMed 7948312]

287. Winston DJ, Ho WG, Bruckner DA et al. Beta-lactam antibiotic therapy in febrile granulocytopenic patients: a randomized trial comparing cefoperazone plus piperacillin, ceftazidime plus piperacillin, and imipenem alone. Ann Intern Med. 1991; 115:849-59. [IDIS 288466] [PubMed 1952471]

288. Ramphal R, Bolger M, Oblon DJ et al. Vancomycin is not an essential component of the initial empiric treatment regimen for febrile neutropenic patients receiving ceftazidime: a randomized prospective study. Antimicrob Agents Chemother. 1992; 36:1062-7. [IDIS 296696] [PubMed 1510394]

289. EORTC International Antimicrobial Therapy Cooperative Group. Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia. N Engl J Med. 1987; 317:1692-8. [IDIS 236268] [PubMed 2892130]

290. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. Ann Intern Med. 1993; 119:584-93. [IDIS 320672] [PubMed 8363169]

291. Sanders JW, Powe NR, Moore RD. Ceftazidime monotherapy for empiric treatment of febrile neutropenic patients: a metaanalysis. J Infect Dis. 1991; 164:907-16. [IDIS 290561] [PubMed 1834751]

292. Feliu J, Artal A, Baron MG et al. Comparison of two antibiotic regimens (piperacillin plus amikacin versus ceftazidime plus amikacin) as empiric therapy for febrile neutropenic patients with cancer. Antimicrob Agents Chemother. 1992; 36:2816-20. [IDIS 306788] [PubMed 1482151]

293. Giamarellou H. Empiric therapy for infections in the febrile, neutropenic, compromised host. Med Clin N Am. 1995; 79:559-77. [PubMed 7752729]

294. Rolston KVI, Berkey P, Bodey GP et al. A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. Arch Intern Med. 1992; 152:283-91. [IDIS 291564] [PubMed 1739355]

295. Charnas R, Luthi AR, Ruch W. Once daily ceftriaxone plus amikacin vs. three time daily ceftazidime plus amikacin for treatment of febrile neutropenic children with cancer. Pediatr Infect Dis J. 1997; 16:346-53. [IDIS 385370] [PubMed 9109134]

296. Stamm WE, Hooton TM. Management of urinary tract infections in adults. N Engl J Med. 1993; 329:1328-34. [IDIS 320913] [PubMed 8413414]

297. Lu DC, Chang SC, Chen YC et al. In vitro activities of antimicrobial agents, alone and in combinations, against Burkholderia cepacia isolated from blood. Diagn Microbiol Infect Dis. 1997; 28:187-91. [PubMed 9327247]

298. Bach MC, Cocchetto DM. Ceftazidime as single-agent therapy for gram-negative aerobic bacillary osteomyelitis. Antimicrob Agents Chemother. 1987; 31:1605-8. [IDIS 235004] [PubMed 3124734]

299. Nicolau DP, Nightingale CH, Banevicius MA et al. Serum bactericidal activity of ceftazidime: continuous infusion versus intermittent injections. Antimicrob Agents Chemother. 1996; 40:61-4. [IDIS 361515] [PubMed 8787880]

300. Benko AS, Cappelletty DM, Kruse JA et al. Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections. Antimicrob Agents Chemother. 1996; 40:691-5. [IDIS 364377] [PubMed 8851594]

301. Kuzemko J, Crawford C. Continuous infusion of ceftazidime in cystic fibrosis. Lancet. 1989; 2:385. [IDIS 258225] [PubMed 2569571]

302. Daenen S, de Vries-Hospers H. Cure of Pseudomonas aeruginosa infections in neutropenic patients by continuous infusion of ceftazidime. Lancet. 1988; 2:937.

303. Carmeli Y, Samore MH. Comparison of treatment with imipenem vs. ceftazidime as a predisposing factor for nosocomial acquisition of Stenotrophomonas maltophilia: a historical cohort study. Clin Infect Dis. 1997; 24:1131-4. [IDIS 388558] [PubMed 9195070]

304. Visalli MA, Jacobs MR, Appelbaum PC. Activities of three quinolones, alone and in combination with extended-spectrum cephalosporins or gentamicin, against Stenotrophomonas maltophilia. Antimicrob Agents Chemother. 1998; 42:2002-5. [IDIS 411418] [PubMed 9687397]

305. Garrison MW, Anderson DE, Campbell DM et al. Stenotrophomonas maltophilia: emergence of multidrug-resistant strains during therapy and in an in vitro pharmacodynamic chamber model. Antimicrob Agents Chemother. 1996; 40:2859-64. [PubMed 9124855]

306. Fass RJ, Barnishan J, Solomon MC et al. In vitro activities of quinolones, beta-lactams, tobramycin, and trimethoprim-sulfamethoxazole against nonfermentative gram-negative bacilli. Antimicrob Agents Chemother. 1996; 40:1412-8. [IDIS 368423] [PubMed 8726011]

307. Pitt TL, Kaufmann ME, Patel PS et al. Type characterization and antibiotic susceptibility of Burkholderia (Pseudomonas) cepacia isolates from patients with cystic fibrosis in the United Kingdom and the Republic of Ireland. J Med Microbiol. 1996; 44:203-10. [PubMed 8636938]

308. Yamagishi Y, Fujita J, Takigawa K et al. Clinical features of Pseudomonas cepacia pneumonia in an epidemic among immunocompromised patients. Chest. 1993; 103:1706-9. [PubMed 7691480]

309. Bhakta DR, Leader I, Jacobson R et al. Antibacterial properties of investigational, new, and commonly used antibiotics against isolates of Pseudomonas cepacia in Michigan. Chemotherapy. 1992; 38:319-23. [IDIS 308266] [PubMed 1283733]

310. Vinks AA, Brimicombe RW, Heijerman HG et al. Continuous infusion of ceftazidime in cystic fibrosis patients during home treatment: clinical outcome, microbiology and pharmacokinetics. J Antimicrob Chemother. 1997; 40:125-33. [IDIS 388352] [PubMed 9249216]

311. De Boeck K, Breysem L. Treatment of Pseudomonas aeruginosa lung infection in cystic fibrosis with high or conventional doses of ceftazidime. J Antimicrob Chemother. 1998; 41:407-9. [IDIS 404269] [PubMed 9578170]

312. Church DA, Kanga JF, Kuhn RJ et al. Sequential ciprofloxacin therapy in pediatric cystic fibrosis: comparative study vs. ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations. The Cystic Fibrosis Study Group. Pediatr Infect Dis J. 1997; 16:97-105. [IDIS 379715] [PubMed 9002118]

313. Rains CP, Bryson HM, Peters DH. Ceftazidime: an update of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs. 1995; 49:577-617. [PubMed 7789291]

314. Lewin C, Doherty C, Govan J. In vitro activities of meropenem, PD 127391, PD 131628, ceftazidime, chloramphenicol, co-trimoxazole, and ciprofloxacin against Pseudomonas cepacia. Antimicrob Agents Chemother. 1993; 37:123-5. [PubMed 8431009]

315. Richard DA, Nousia-Arvanitakis S, Sollich V et al. Oral ciprofloxacin vs. intravenous ceftazidime plus tobramycin in pediatric cystic fibrosis patients: comparison of antipseudomonas efficacy and assessment of safety with ultrasonography and magnetic resonance imaging. Pediatr infect Dis J. 1997; 16:572-8. [IDIS 388806] [PubMed 9194107]

316. Adu A, Armour CL. Drug utilisation review (DUR) of the third generation cephalosporins: focus on ceftriaxone, ceftazidime and cefotaxime. Drugs. 1995; 50:423-39. [PubMed 8521766]

317. Rubinstein E, Lode H, Grassi C et al. Ceftazidime monotherapy vs. ceftriaxone/tobramycin for serious hospital-acquired gram-negative infections. Clin Infect Dis. 1995; 20:1217-28. [IDIS 347166] [PubMed 7620002]

318. Smith CE, Tillman BS, Howell AW et al. Failure of ceftazidime-amikacin therapy for bacteremia and meningitis due to Klebsiella pneumoniae producing an extended-spectrum β-lactamase. Antimicrob Agents Chemother. 1990; 34:1290-3. [IDIS 267832] [PubMed 2203306]

319. Burwen DR, Banerjee Sn, Gaynes RP, and the National Nosocomial Infections Surveillance System. J Infect Dis. 1994; 170:1622-5.

320. Rice LB, Eckstein EC, DeVente J et al. Ceftazidime-resistant Klebsiella pneumoniae isolates recovered at the Cleveland Department of Veterans Affairs Medical Center. Clin Infect Dis. 1996; 23:118-24. [IDIS 369504] [PubMed 8816140]

321. Thomson KS, Sanders CC, Washington JA. High-level resistance to cefotaxime and ceftazidime in Klebsiella pneumoniae isolates from Cleveland, OH. Antimicrob Agents Chemother. 1991; 35:1001-3. [IDIS 281931] [PubMed 1854155]

322. Naumovski L, Quinn JP, Miyashiro D et al. Outbreak of ceftazidime resistance due to a novel extended-spectrum β-lactamase in isolates from cancer patients. Antimicrob Agents Chemother. 1992; 36:1991-6. [IDIS 302695] [PubMed 1416892]

323. Quinn JP, Miyashiro D, Sahm D et al. Novel plasmid-mediated β-lactamase (TEM-10) conferring selective resistance to ceftazidime and aztreonam in clinical isolates of Klebsiella pneumoniae. Antimicrob Agents Chemother. 1989; 33:1451-6. [PubMed 2684007]

324. Spangler Sk, Visalli MA, Jocobs MR et al. Susceptibilities of non-Pseudomonas aeruginosa gram-negative nonfermentative rods to ciprofloxacin, ofloxacin, levofloxacin, D-ofloxacin, sparfloxacin, ceftazidime, piperacillin, piperacillin-tazobactam, trimethoprim-sulfamethoxazole, and imipenem. Antimicrob Agents Chemother. 1996; 40:772-5. [IDIS 364382] [PubMed 8851609]

325. Dance DAB, Wuthiekanun V, Chaowagul W et al. Development of resistance to ceftazidime and co-amoxiclav in Pseudomonas pseudomallei. J Antimicrob Chemother. 1991; 28:321-3. [PubMed 1723404]

326. Smith MD, Wuthiekanun V, Walsh AL et al. In-vitro activity of carbapenem antibiotics against β-lactam susceptible and resistant strains of Burkholderia pseudomallei. J Antimicrob Chemother. 1996; 37:611-5. [IDIS 365664] [PubMed 9182118]

327. Smith MD, Wuthiekanun V, Walsh AL et al. Susceptibility of Pseudomonas pseudomallei to some newer β-lactam antibiotics and antibiotic combinations using time-kill studies. J Antimicrob Chemother. 1994; 33:145-9. [IDIS 325075] [PubMed 7512547]

328. Lecso-Bornet M, Bérgogne-Berezin E. Susceptibility of 100 strains of Stenotrophomonas maltophilia to three β-lactams and five β-lactam-β-lactamase inhibitor combinations. J Antimicrob Chemother. 1997; 40:717-20. [IDIS 398250] [PubMed 9421322]

329. Young RJ, Lipman J, Gin T et al. Intermittent bolus dosing of ceftazidime in critically ill patients. J Antimicrob Chemother. 1997; 40:269-73. [IDIS 392553] [PubMed 9301994]

330. Godfrey AJ, Wong S, Dance DAB et al. Pseudomonas pseudomallei resistance to β-lactam antibiotics due to alterations in the chromosomally encoded β-lactamase. Antimicrob Agents Chemother. 1991; 35:1635-40. [IDIS 286411] [PubMed 1718214]

331. Poulos CD, Matsumura SO, Willey BM et al. In vitro activities of antimicrobial combinations against Stenotrophomonas (Xanthomonas) maltophilia. Antimicrob Agents Chemother. 1995; 39:2220-3. [PubMed 8619571]

332. David TJ, Devlin J. Continuous infusion of ceftazidime in cystic fibrosis. Lancet. 1989; 1:1454-5. [IDIS 256607] [PubMed 2567466]

333. Wolter JM, Bowler SD, Nolan PJ et al. Home intravenous therapy in cystic fibrosis: a prospective randomized trial examining clinical, quality of life and cost aspects. Eur Respir J. 1997; 10:896-900. [PubMed 9150331]

334. Pitkin DH, Sheikh W, Nadler HL. Comparative in vitro activity of meropenem versus other extended-spectrum antimicrobials against randomly chosen and selected resistant clinical isolates tested in 26 North American centers. Clin Infect Dis. 1997; 24(Suppl 2):S238-48.

335. Quagliarello VJ, Scheld WM. Treatment of bacterial meningitis. N Engl J Med. 1997; 336:708-16. [IDIS 388664] [PubMed 9041103]

336. American Academy of Pediatrics Committee on Infectious Diseases. Therapy for children with invasive pneumococcal infections. Pediatrics. 1997; 99:289-99. [IDIS 381500] [PubMed 9024464]

337. Tunkel AR, Scheld WM. Issues in the management of bacterial meningitis. Am Fam Physician. 1997; 56:1355-62. [IDIS 393071] [PubMed 9337758]

338. Townsend GC, Scheld WM. Infections of the central nervous system. Adv Intern Med. 1998; 43:403-47. [PubMed 9506189]

340. Cohen SH, Gerding DN, Johnson S et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol. 2010; 31:431-55. [PubMed 20307191]

341. Fekety R for the American College of Gastroenterology Practice Parameters Committee. Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. Am J Gastroenterol. 1997; 92:739-50 (IDIS 386628) [IDIS 386628] [PubMed 9149180]

342. American Society of Health-System Pharmacists Commission on Therapeutics. ASHP therapeutic position statement on the preferential use of metronidazole for the treatment of Clostridium difficile-associated disease. Am J Health-Syst Pharm. 1998; 55:1407-11. [IDIS 407213] [PubMed 9659970]

344. Bonacorsi S, Fitoussi F, Lhopital S et al. Comparative in vitro activities of meropenem, imipenem, temocillin, piperacillin, and ceftazidime in combination with tobramycin, rifampin, or ciprofloxacin against Burkholderia cepacia isolates from patients with cystic fibrosis. Antimicrob Agents Chemother. 1999; 43:213-7. [IDIS 423034] [PubMed 9925508]

345. Yu WL, Wang DY, Lin CW et al. Endemic Burkholderia cepacia bacteraemia: clinical features and antimicrobial susceptibilities of isolates. Scand J Infect Dis. 1999; 31:293-8. [PubMed 10482060]

346. Simpson AJH, Suputtamongkol Y, Smith MD et al. Comparison of imipenem and ceftazidime as therapy for melioidosis. Clin Infect Dis. 1999; 29:381-7. [IDIS 434516] [PubMed 10476746]

347. Mullen CA, Petropoulos D, Roberts WM et al. Outpatient treatment of fever and neutropenia for low risk pediatric cancer patients. Cancer. 1999; 86:126-34. [IDIS 431219] [PubMed 10391572]

348. Bosso JA, Bonapace CR, Flume PA et al. A pilot study of the efficacy of constant-infusion ceftazidime in the treatment of endobronchial infections in adults with cystic fibrosis. Pharmacotherapy. 1999; 19:620-6. [IDIS 425144] [PubMed 10331825]

349. Lindblad R, Rodjer S, Adriansson M et al. Empiric monotherapy for febrile neutropenia—a randomized study comparing meropenem with ceftazidime. Scand J Infect Dis. 1998; 30:237-43. [PubMed 9790130]

350. Sobraques M, Maurin M, Birtles RJ et al. In vitro susceptibilities of four Bartonella bacilliformis strains to 30 antibiotic compounds. Antimicrob Agents Chemother. 1999; 43:2090-2. [IDIS 433952] [PubMed 10428946]

351. Aracil B, Gomez-Garces JL, Alos JI. A study of susceptibility of 100 clinical isolates belonging to the Streptococcus milleri group to 16 cephalosporins. J Antimicrob Chemother. 1999; 43:399-402. [IDIS 425875] [PubMed 10223596]

352. Hern JD, Ghufoor K, Jayaraj SM et al. ENT manifestations of Pseudomonas aeruginosa infection in HIV and AIDS. Int J Clin Pract. 1998; 52:141-4. [IDIS 404400] [PubMed 9684426]

353. Johnson MP, Ramphal R. Malignant external otitis: report on therapy with ceftazidime and review of therapy and prognosis. Clin Infect Dis. 1990; 12:173-80.

354. Tunkel AR, Harman BJ, Kaplan SL et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis. 2004; 39:1267-84. [IDIS 537717] [PubMed 15494903]

355. Currie BJ. Melioidosis: an important cause of pneumonia in residents of and travelers returned from endemic regions. Eur Respir J. 2003; 22:542-50. [PubMed 14516149]

356. US Army Medical Research Institute of Infectious Disease. USAMRIID’s medical management of biological casualties handbook. 7th ed. USAMRIID: Fort Detrick, MD; 2011 Sep: 45-542.

357. Bossi P, Tegnell A, Baka A et al. BICHAT guidelines for the clinical management of glanders and melioidosis and bioterrorism-related glanders and melioidosis. Euro Surveill. 2004; 9:1-6.

358. Centers for Disease Control and Prevention. Imported melioidosis–South Florida, 2005. MMWR Morb Mortal Wkly Rep. 2006; 55:873-6. [PubMed 16915220]

390. Freifeld AG, Bow EJ, Sepkowitz KA et al. Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Disease Society of America. Clin Infect Dis. 2011; 52:e56-93.

a. AHFS Drug Information 2003. McEvoy GK, ed. Cephalosporins General Statement. Bethesda, MD: American Society of Health-System Pharmacists; 2003:125-39.

HID. Trissel LA. Handbook on injectable drugs. 17th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2013:231-41.